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Temporal lobe epilepsy is the 
most common form of acquired 
epilepsy. This thesis explored the 
interaction between the cellular 
reorganization processes occurring 
during epileptogenesis, their 
functional implications, and the role 
of the urokinase-type plasminogen 
activator (uPA) and its receptor 
(uPAR) in epileptogenic network 
alterations. It shows that components 
of epileptogenic network alterations 
may have different temporal 
profiles, and the Plau and Plaur 
genes encoding for uPA and uPAR 
respectively are modifier genes for 
acquired epileptogenesis.
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ABSTRACT
Epileptogenesis refers to a phenomenon whereby an initial brain damaging insult such as status
epilepticus (SE), stroke, infection, or traumatic brain injury triggers a cascade of molecular and
cellular alterations that ultimately results in the occurrence of spontaneous seizures. These
alterations which include neurodegeneration, gliosis, neurogenesis, granule cell layer dispersion,
mossy fiber sprouting, inflammation, blood-brain barrier disruption and angiogenesis, are well
characterized; however, the molecular mechanisms that underlie them are poorly understood.
The aim of this thesis is to study the interaction(s) between the cellular reorganization
processes in the hippocampus during epileptogenesis, and in particular vascular and neuronal
plastic events, since common trophic stimuli drive vascular and nerve network formation. Next,
the molecular mechanisms that underlie these network alterations will be studied. The urokinase-
type plasminogen activator (uPA) and its receptor (uPAR) were selected as a possible candidate
mechanism, because; there is an increased expression of uPA-uPAR during epileptogenesis.
Furthermore, uPA-uPAR has implications in various cellular reorganization processes, including
cell proliferation, migration and survival.
The pilocarpine-induced SE rat model and the intrahippocampal kainic acid-induced SE
mouse model were employed in studying the interactions of the reorganization processes, and role
of  uPA  and  uPAR  in  these  processes,  with  the  aid  of  immunohistochemistry  methods.  The
development of epilepsy was monitored using video-electroencephalography. Magnetic resonance
imaging (MRI) was used to study the functional outcome of vascular remodeling during
epileptogenesis.
The results demonstrate that the epilepsy phenotype following SE is severe in uPAR
deficiency, where as it remains unchanged in uPA deficiency. SE induces vascular break down,
followed by a progressive build-up of blood vessels.  This process of vascular build-up is severely
impaired in uPAR deficiency but not uPA deficiency. Nonetheless, the vessel length changes
correlate with cerebral blood volume increase in the hippocampus but lack association with
neurodegeneration, neurogenesis or axonal sprouting. uPAR or uPA deficiency affects neuronal
plastic events such as neurodegeneration and neurogenesis, but not mossy fiber sprouting.
Furthermore, uPAR deficiency results in a delayed acute but chronic inflammatory response.
In conclusion, this study demonstrates that the components of epileptogenic network
alterations may have different temporal profiles during epileptogenesis. However, the uPA-uPAR
system is a part of the underlying mechanisms involved in the generation of these network
alterations. This suggests that the Plau and Plaur genes encoding for uPA and uPAR respectively
are modifier genes for acquired epileptogenesis.
National Library of Medicine Classification: WL 385, WL 300, WL 302, WL 102.5, QU 142
Medical Subject Headings: Status Epilepticus; Epilepsy; Blood Vessels; Brain; Cerebrovascular Circulation;
Neurons; Nerve Net; Neural Pathways; Neuronal Plasticity; Nerve Degeneration; Neurogenesis; Urokinase-
Type Plasminogen Activator; Receptors, Urokinase Plasminogen Activator; Hippocampus; Disease Models,
Animal; Rats; Mice
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ABSTRAKTI
Epileptogeneesi tarkoittaa epilepsian kehittymistä, jonka voi käynnistää status epilepticus,
aivoverenkiertohäiriö, infektio tai pään vamma (symptomaattinen epilepsia). Muutokset
molekyyli- ja solutasolla kuten hermosoluvaurio, hermotukisolujen lisääntyminen,
sammalsäikeiden versominen, veriaivoesteen vaurio ja verisuonten uudismuodostus voivat
lopulta johtaa spontaaneihin toistuviin kohtauksiin. Vaikka tämä tapahtumaketju on hyvin
selvillä, sen molekyylitason mekanismit tunnetaan vielä huonosti.
Tässä väitöskirjatyössä selvitettiin hippokampuksen alueella tapahtuvia neurobiologisia
muutoksia epileptogeneesin aikana.  Erityisen mielenkiinnon kohteena olivat verisuonten ja
hermosolujen muovautuvuutta säätelevät molekyylitason mekanismit. Tutkimukseen valittiin
urokinaasityyppinen plasminogeeniaktivaattori (uPA) ja sen reseptori (uPAR), sillä aikaisemmat
tutkimukset ovat osoittaneet, että uPA:n ja uPAR:in ilmentyminen on lisääntynyt epilepsian
kehittymisen aikana. Tämä on myös yhteydessä solutason uudelleenjärjestäytymiseen (mm.
solujen uudismuodostus, kulkeutuminen ja hengissäsäilyminen).
Kokeissa status epilepticus aiheutettiin rotalle pilokarpinnilla ja uPA/uPAR poistogeenisille
hiirille hippokampukseen injisoidulla kainihapolla. uPA/uPAR:in osuutta kudosten
uudelleenjärjestäytymisessä tutkittiin immunohistokemiallisin menetelmin. Epilepsian
kehittymistä seurattiin video-EEG:llä ja verisuonimuutoksia magneettikuvausta käyttäen.
Tulokset osoittivat, että epilepsian ilmentyminen status epilepticuksen jälkeen on
sidoksissa uPAR:in poistogeenisyyteen. Status epilepticus aiheutti myös häiriön veriaivoesteen
toiminnassa, jota seurasi asteettainen lisääntynyt verisuonten uudismuodostus. Tämä prosessi oli
sidoksissa uPAR:in ilmentymiseen. Muutokset verisuonten pituudessa korreloivat verenkierron
lisääntymiseen hippokampuksen alueella, mutta eivät hermosoluvaurioon, hermosolujen
uudismuodostukseen tai hermosäikeiden versomiseen. uPA/uPAR:in poistogeenisyys vaikutti
hermosolujen muovautuvuuteen (mm. hermosoluvaurio ja hermosolujen uudismuodostus), mutta
ei sammalsäikeiden versomiseen. Lisäksi status epilepticus aiheutti viivästyneen tulehdusreaktion,
joka muuttui krooniseksi uPAR poistogeenisillä hiirillä.
Yhteenvetona voidaan todeta, että hermosolujen ja verisuonten uudismuodostuksella ja
tulehdusreaktiolla on erilainen ajallinen yhteys epileptogeneesiin. uPA:ta ja uPAR:ta koodittavilla
geeneillä, Plau ja Plaur, on tärkeä merkitys hermokudoksen muovautumisessa ja symptomaattisen
epilepsian kehittymisessä
Luokitus: WL 385, WL 300, WL 302, WL 102.5, QU 142
Yleinen suomalainen asiasanasto: epilepsia; aivot; hippokampus; verisuonet; hermosolut; plastisuus;
verkostoituminen; koe-eläimet
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1. Introduction
Epilepsy is one of the most common neurological disorders, affecting approximately 1% of
the world’s population. Temporal lobe epilepsy (TLE) is the most common form of
symptomatic epilepsy (Engel, 1996b). Patients with TLE have usually had an initial
precipitating brain injury (initial insult) earlier on in life, which can be in the form of status
epilepticus (SE), head trauma, a stroke, tumor or infection. The initial precipitating insult
is the first phase in the development of TLE. The next phase, the latency phase, is void of
signs and symptoms of disease. However, during this phase there are cellular and
molecular reorganization processes going on in the brain including neurodegeneration,
gliosis, neurogenesis, inflammation, gene expression, axonal plasticity, secretion of growth
factors and angiogenesis, which eventually make the brain prone to seizures. In the last
phase of the disease, the patient starts experiencing spontaneous seizures. During this
phase, there is still ongoing tissue remodeling (Pitkänen and Lukasiuk, 2009). These
cellular reorganization events are well characterized, and their severity is associated with
the severity of the epilepsy (Pitkänen et al., 2007).
Epileptogenic cellular reorganization processes involve the cell-extracellular matrix
(ECM), cell-cell interaction; and cell signaling. The urokinase-type plasminogen activator
(uPA) and its receptor (uPAR), elements of the plasminogen activator (PA) system, have
implications in these sorts of interactions and signaling events (Sidenius and Blasi, 2003).
The uPA and uPAR play a role in physiological and pathological events that require tissue
remodeling (Floridon C. et al., 1999; Smith and Marshall, 2010). Interestingly, there is an
increased expression of uPA and uPAR in the hippocampus during epileptogenesis
(Lahtinen et al., 2006, 2009; Iyer et al., 2010; Liu et al., 2010). This suggests that uPA-uPAR
may be involved in tissue reorganization during epileptogenesis. There is a growing
interest in understanding the molecular mechanisms underlying these epileptogenic
network alterations. Elucidating these mechanisms may provide new biomarkers and
treatment targets for epilepsy.
The aim of this thesis is to elucidate the interactions and functional implications of
the cellular reorganization processes during epileptogenesis. The study focuses,
particularly, on deciphering the relationship between angiogenesis and neuronal network
alterations such as neurodegeneration, neurogenesis and axonal sprouting in the
hippocampus, since common trophic stimuli regulate vascular and nerve network
formation (Carmeliet and Tessier-Lavigne, 2005). In addition, the role of uPA and uPAR as
a possible mechanism underlying epileptogenic network alterations was investigated. This
was studied effectively using uPA and uPAR deficiency mice in a mouse model of
temporal lobe epilepsy.
2
32. Review of the literature
2.1 EPILEPSY
2.1.1 Definition of epileptic seizure and epilepsy
According to the International League Against Epilepsy (ILAE) and the International
Bureau  for  Epilepsy,  an  epileptic  seizure  is  a  transient  occurrence  of  signs  and/or
symptoms due to abnormal excessive or synchronous neuronal activity in the brain (ILAE,
Fisher et al., 2005). Epilepsy is a disorder of the brain characterized by an enduring
predisposition to generate epileptic seizures and by neurobiologic, cognitive, physiological
and social consequences of this condition. The definition of epilepsy should include a
history of at least one seizure (ILAE, Fisher et al., 2005).
2.1.2 Classification of seizures and epilepsies
Seizures are classified as either partial or generalized seizures (ILAE, 1981). Partial
seizures involve a network limited to one hemisphere and generalized seizures are
widespread, involving bilateral cortical networks (ILAE, 1981).
The classification of epilepsies and epilepsy syndromes is based on clinical features
together with appropriate EEG and brain imaging investigations. Epileptic syndromes are
either focal epilepsies (partial-onset seizures) or generalized epilepsies (generalized
seizures) (ILAE, 1989). However, as a result of fast technological and scientific advances,
there is a growing concern for revising the concepts, terminology and approaches for
classifying seizures and epilepsies. The ILAE's Commission on Classification and
Terminology has made proposals which will incorporate these advances (for details see
Berg et al., 2010).
2.1.3 Temporal lobe epilepsy (TLE) and the concept of epileptogenesis
Often  referred  to  as  limbic  epilepsy,  TLE  is  the  most  common  symptomatic  epilepsy
(Engel, 1996b). The seizures arise from the temporal lobe structures or limbic system,
which includes the hippocampus, amygdala, subicular complex, entorhinal and
parahippocampal cortices (Engel, 1996a). The habitual seizures begin with an aura
followed by other symptoms referable to the limbic system, including epigastric rising,
emotional change (typically fear) and occasionally olfactory or gustatory hallucinations
(Williamson and Engel, 1997).
Patients with TLE usually have a history of febrile seizures or initial precipitating
injuries such as a head trauma, infection, stroke, tumor or SE early on in life, suggesting
that the development of TLE begins with a brain insult (Mathern et al., 1995, 1997). The
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(epileptogenesis  or  the  latency  phase),  lasts  from  several  months  to  years.  It  is  void  of
seizures but is characterized by tissue remodeling changes that make the brain prone to
develop seizures. In the final phase, epileptogenic network reorganization continues after
epilepsy diagnosis (Jutilia et al., 2002; Pitkänen and Lukasiuk, 2009). The process of
epileptogenesis is illustrated in figure 1.
 Hippocampal sclerosis is a typical, pathological hallmark often associated with
TLE.  It has been described in 60-70% of patients with intractable TLE. Its characteristics
include loss of pyramidal neurons and gliosis in the CA1 and CA3 subfields of the
hippocampus (Jutilia et al., 2001; Kälviäinen and Salmenperä, 2002). In addition, there is
dentate hilar cell loss and extrahippocampal pathology in the amygdala and entorhinal
cortex including the thalamus (Blumcke et al., 2002; Wieser et al., 2004).
Current treatment of epilepsy focuses on the prevention of seizures. Following
adequate medical treatment, patients can become seizure free. However, a handful of
them, about 30%, become refractory (Hauser and Hesdorffer 1990). A subgroup of patients
may obtain relief from epilepsy surgery by resecting the epileptic focus (Bertram, 2009).
Figure 1. The process of epileptogenesis in symptomatic epilepsy. The initial brain insult (head
trauma, infection, status epilepticus, or stroke) initiates epileptogenesis characterized by
several cellular and molecular reorganization processes, leading ultimately to the appearance
of spontaneous recurrent seizure, i.e. epilepsy (modified from Pitkänen and Sutula, 2002).
2.1.4 Status epilepticus (SE)
Status epilepticus is a single clinical seizure or repeated seizures lasting more than 30
minutes  without  intervention or  recovery of  consciousness  (ILAE,  1989;  Waterhouse and
Delorenzo, 2001). However, seizure activity persisting more than 5 minutes is considered
to be SE and is treated accordingly (Alldredge et al., 2001). According to epidemiological
studies in Switzerland, Germany, Italy, and among the white population of the USA, SE
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of  SE  in  children  is  febrile  seizures  or  infections,  while  in  adults  it  is  cerebrovascular
accidents, hypoxia, metabolic causes and low antiepileptic drug levels (DeLorenzo et al.,
1996; Knake et al., 2001).
The risk of developing epilepsy after pediatric convulsive SE is within a wide range
of 13-74% (Raspall-Chaure et al., 2006). The risk is 25-40% after 2 years following the first
unprovoked SE (Hesdorffer et al., 1998; Eriksson and Koivikko, 1997). In adults, the risk of
developing epilepsy after SE is about 42%, 10 years later (Hesdorffer et al., 1998). Lower
risk in children is due to the higher resistance of the juvenile brain against neuronal
damage (Sperber EF et al., 1991). In experimental settings, regardless of the model used
(pilocarpine, kainic acid or electrical stimulation), about 50-100% of animals develop
spontaneous seizures (Hellier et al., 1999; Holtkamp et al., 2005; Goffin et al., 2007).
2.2 NEUROPATHOLOGY OF TEMPORAL LOBE EPILEPSY
2.2.1 Hippocampal neurodegeneration
Hippocampal neurodegeneration is the most common lesion in patients with temporal
lobe epilepsy. 50-70% of patients with medically intractable limbic epilepsy have
hippocampal neurodegeneration (Honavar and Meldrum, 1997). In hippocampal
neurodegeneration, there is loss of neurons in the hippocampal pyramidal cell layer (CA1,
CA2  and  CA3)  and  the  dentate  hilus.  There  is  relative  preservation  of  the  CA2  neurons
and the dentate granule cells. Often neuronal loss is accompanied by dense gliosis
(Blumke et al., 2002; Majores et al., 2007). In conjunction with hippocampal
neurodegeneration are neuronal loss in the neighboring entorhinial cortex and the
amygdala (Dawodu and Thom, 2005; Pitkänen and lukasiuk, 2009). Severe seizures and SE
induce neuronal cell death in the hippocampus within hours of seizure onset (Hauser,
1983). The question still remains whether hippocampal neurodegeneration is the
consequence of repeated seizures or whether it plays a role in the development of epileptic
focus (Jefferys, 1999; Berkkovic and Jackson, 2000).
Animal models of human TLE also demonstrate hippocampal neurodegeneration.
In particular, animal models of SE show that hippocampal excitatory principal cells of the
CA1 and CA3 subfields and hilar neurons of the dentate gyrus are relatively sensitive to
seizure-induced death. These models also demonstrate that dentate granule cells are
relatively resistant to damage (Franck, 1984; Sloviter, 1987; Morimoto et al., 2004). Like in
humans, neuronal cell death is seen in the amygdala, entorhinal, perirhinal and
parahippocampal cortices. Dying neurons can be seen a few hours after SE and
neurodegeneration may continue for up to 2 months (Pitkänen and Sutula, 2002).
62.2.2 Granule cell dispersion (GCD)
Granule cell dispersion (GCD) is a morphological hallmark observed in the sclerotic
hippocampus of TLE patients (Houser, 1990). In GCD, there is a loss of close apposition
between the granule cell soma, enlargement of the stratum granulosum and the presence
of granule cells scattered in the molecular layer. About 40% of sclerotic hippocampal
specimens from TLE patients show GCD (Thom et al., 2002). The extent of granule cell
layer dispersion correlates with the amount of neuronal cell death in the hippocampus and
hilus of the dentate gyrus (Houser, 1990, Thom et al., 2002). Lurton and colleagues (1998)
found  that  GCD  was  more  likely  to  occure  in  TLE  patients  with  early  epileptic  events,
arising during the first 4 years of life, and is not associated with the duration or number of
seizures later on in life.  However, animal studies have so far failed to show any
connection between GCD and seizure activity. The mechanisms inducing these
morphological changes and to what extent GCD contributes to seizure activity remains
unknown. However, current reports suggest reelin dysfunction causes GCD dispersion,
since reelin is essential for the maintenance of layered structures in an adult brain and
reelin deficiency is correlated with GCD in TLE patients (see review by Haas and
Frotscher, 2010).
2.2.3 Gliosis
Gliosis refers to the proliferation and activation of glial cells.  It is a prominent
histopathological  hallmark  associated  with  TLE.  It  is  only  recently  that  its  role  in  the
development of epilepsy was fully appreciated (Yang et al., 2010). There are four major
types  of  glia  cells  involved  in  gliosis:  astrocytes,  microglia,  oligodendrocytes  and  NG2
cells  (Polydendrocytes).  These  cells  play  diverse  roles  in  the  normal  and  pathological
brain.  However,  astrocytes  and microglia  are  the  most  widely  studied and also  the  cells
most implicated in TLE pathology.
Astrocytes constitute 20-50% of the volume in most brain areas (Bruzzone and
Giaume, 1999). Astrocytes end-feet make contact with blood vessels and thus are an
essential element of the blood-brain barrier (BBB) and as such control cerebral blood flow
(Heneka et al., 2010). They also make contact with other cell types including neurons.
Some of the most widely investigated roles of astrocytes include regulation of extracellular
potassium, glutamate uptake and synaptic glutamate concentrations, metabolism and
synthesis of various molecules. They also play a crucial role in synaptic transmission and
seizure as well as in inflammation (Vezzani et al., 2007; Wetherington et al., 2008).
In a healthy brain, microglia are constantly surveying their environment
(Nimmerjahn et al., 2005). In this way they are able to intervene in a host of events such as
synaptic pruning during postnatal development (Katz and Shatz, 1996; Hua and smith,
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phagocytosis of apoptotic newborn neurons, regulation of neuronal activity by interaction
with synapses and astrocytes, and reorganization of neuronal circuits (see review by
Napoli and Neumann, 2009). Most investigations on microglial function in the last decade
show that they are a key player in brain injury and disease. In response to a brain injury,
microglia become activated, proliferates, migrate or secrete compound into the
extracellular matrix in a process generally termed microgliosis (Hailer, 2008). Studies
using animal models show that microglial activation peaks at 3-5 days after a brain injury
and can remain elevated for several weeks (Jorgensen et al., 1993; Hailer et al., 1999). Some
of the compounds secreted by microglia may be harmful to neurons while others may be
beneficial. Some of the harmful compounds include proinflammatory cytokines
(interleukin-1, interleukin-6, tumor necrotic factor ), proteases and nitric oxide
(Benveniste, 1992; Nathan, 1992; Kreutzberg, 1996). Secreted neuroprotective compounds
include transforming growth factor , brain-derived neurotrophic factor (BDNF) and the
nerve growth factor. Other beneficial actions of microglia include clearing the dying
neurons and glia. The net effect of the harmful and beneficial actions of microglia on the
development and progression of TLE remains to be studied.
2.2.4 Mossy fiber sprouting
Sprouting  of  granule  cell  axons  or  mossy  fiber  is  one  of  the  most  extensively  studied
features of human TLE (Mathern et al., 1996; Sutula and Dudek, 2007). Animal models of
epilepsy also demonstrate this feature, particularly models that utilize prolonged SE for
the induction of chronic epilepsy (Pitkänen et al., 2007). Mossy fiber sprouting refers to
changes  in  axonal  projection  of  dentate  granule  cells.  Normally,  granule  cell  axons
innervate hilar interneurons or the apical dendrites of the CA3 pyramidal neurons. In
human and animal models of TLE, mossy fiber forms synapses with granule cell dendrites
in  the  inner  molecular  layer  and  the  basal  dendrites  of  CA3  pyramidal  cells  of  the
hippocampus (Represa et al., 1990). Experimental studies show that sprouting occurs
before spontaneous seizures and stays throughout the life-time of experimental animals
(Nissinen et al., 2001).
The functional consequence of mossy fiber sprouting remains controversial. Earlier
reports suggest that mossy fiber creates monosynaptic excitatory loops that contribute to
recurrent excitation and thus enhances susceptibility to seizures (Sutula and Dudek, 2007).
However, a recent study by Buckmaster and Lew (2011) shows that suppression of mossy
fiber sprouting does not reduce seizure frequency, thus suggesting that mossy fiber
sprouting is neither pro- nor anticonvulsant. Their finding corroborates with earlier claims
by Harvey and Sloviter (2005) that granule cells become progressively less excitable rather
8than hyperexcitable as mossy fiber sprouting progresses, and granule cells do not initiate
spontaneous behavioral seizures.
2.2.5 Neurogenesis
Erikson and colleagues (1998) provided the first evidence that neurogenesis occurs in the
adult human brain. In adult human and rodent brains, neurogenesis occurs continuously
in the subventricular zone (SVZ) and the subgranular zone (SGZ) (Eriksson et al., 1998;
Benraiss et al., 2001; Bengzon et al., 1997). Other than normal physiological neurogenesis,
several stimuli can increase neurogenesis in experimental animals. Examples include
exercise, enriched environment, adrenal steroids, and glutamatergic neurotransmission
(Gage et al., 1998; Brown et al., 2003).
Despite the difficulty in labeling newly generated neurons in humans with TLE,
evidence of neurogenesis was demonstrated in specimens from patients with TLE using
markers labeling neural progenitors and immature neurons (Blümcke et al., 2001;
Hermann et al., 2006). Several experimental animal studies show compelling evidence of
seizure-promoting effects on neurogenesis. Increased neurogenesis occurs in a variety of
animal models of epilepsy, including rapid animal kindling (Parent et al., 1998; Scott et al.,
1998; Smith et al., 2005), electroconvulsive seizures (Segi-Nishida et al., 2008), the flurothyl
kindling model (Ferland et al., 2002) and pentylenetetrazol seizures (Jiang et al., 2003).
It is unclear how these newly generated neurons integrate in the local neuronal
network  and  whether  they  are  anti-  or  pro-epileptogenic.  A  majority  of  the  newly  born
neurons migrate into the granule cell layer. Following prolonged seizure events some
newly generated neurons migrate aberrantly into the hilus and molecular layer and
differentiate into ectopic dentate granular cells (Parent et al., 2006). Recently, Kron et al.
(2010) showed that newly generated neurons are vulnerable to seizure-induced abnormal
plasticity. They also showed that these neurons may contribute to epileptogenic network
dysfunction. Despite multiple experiments on seizure-induced neurogenesis in animal
models, the role of this phenomenon in ictogenesis and epileptogenesis remains unclear.
2.2.6 Inflammation
Chronic brain inflammation, which comprises the activation of microglia, astrocytes,
endothelial cells of the BBB, peripheral immune cells and the production of inflammatory
mediators, is a prominent feature in human TLE and animal models (Zimmer et al., 1997;
Bien et al., 2007).  Several inflammatory mediators, including NFB, interferons,
interleukins, chemokines, adhesion molecules, and toll-like receptor 4 (TLR4) are reported
in  brain  tissue  from  patients  with  TLE  (see  review  by  Choi  and  Koh,  2008).  Recent
9evidence, especially from experimental animal models indicates that inflammation might
be a consequence as well as a cause of epilepsy.
Experimental animal models of epilepsy are providing information on the role of
inflammation in seizures and the development of epilepsy. In these models, acute seizures
cause activation of microglia and astrocytes, increase expressions of inflammatory related
transcription factors and cytokines such as IL1, TNF-, TGF-1, and neuropeptide
mRNAs (Zimmer et al., 1997; Palata-salaman et al., 2000). Turrin and Rivest (2004) showed
that following pilocarpine induced status epilepticus, the expression of toll-like receptor 2
(TLR2) in microglia increases, leading to the activation of cytokines and chemokines, and
MHC class I and II molecules. Evidence also suggests that activated glia and elevated
cytokines can in turn contribute to seizure-related hippocampal pathology such as
neuronal  death,  neurogenesis,  gliosis  and  mossy  fiber  sprouting  (McNamara et al., 1994;
Parent and Lowenstein, 1997; Koh et al., 1999; Jankowsky and Patterson, 2007).
Experimental evidence suggests that inflammation can lead to neuronal excitability and
neuronal injury either directly, by interacting with glutamatergic neurotransmission or
indirectly, by activation of gene transcription (Viviani et al., 2003; Ravizza et al., 2008).
2.2.7 Angiogenesis and blood-brain barrier (BBB) disruption
Angiogenesis  is  the  process  that  refers  to  the  growth of  new blood vessels  from existing
ones by the proliferation of endothelial cells. Angiogenesis occurs during physiological
and pathological conditions. In the brain, blood capillaries are composed of endothelial
cells  that  line  together  forming a  luminal  structure  and are  connected by tight  junctions.
The abluminal surface of the endothelial cells is covered with a basement membrane,
pericytes, and astrocytes’ end-feet, together forming the BBB. The BBB protects the brain
from toxins in the blood while allowing essential metabolites to cross. Disruption of the
BBB and subsequent angiogenesis occurs in several central nervous system (CNS) disease
pathologies, including traumatic brain injuri (TBI), strokes and human TLE (Morgan et al.,
2007; Rigau et al., 2007; Tang et al., 2007). However, the question still remains whether
vascular remodeling contributes to the pathogenesis of these diseases including epilepsy.
There is evidence suggesting an association between angiogenesis and seizure
susceptibility in experimental animal models of status epilepticus (Rigau et al., 2007). Also,
electroconvulsive seizures can cause endothelial cell proliferation and increase vascular
density in the rat hippocampus (Hellsten et al., 2005). These evidences indicate that both
epileptogenic brain injuries and brief seizures can trigger an increase in brain vascularity.
Angiogenesis may be relevant for optimal functional recovery in an epileptogenic brain,
providing oxygen and nutrients needed for tissue remodeling. However, questions remain
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concerning how this phenomenon is related to seizure frequency or patterns of neuronal
plasticity that favor hyperexcitability.
There are many molecules that affect the development of both the vascular system
and the nervous system. Striking evidence stems from the recent recognition that classical
axon-guidance cues, such as netrin, semaphorins, slits and ephrins also mediate the
navigation of blood vessels along predestined tracts during development (Carmeliet and
Tessier-Lavigne, 2005). Similarly, the angiogenic factor, the vascular endothelial growth
factor (VEGF), regulates the migration of various neuron types to their final destination
(Schwarz et al., 2004). This evidence suggests that in the presence of such trophic stimuli
one would expect an association between angiogenesis and neuronal plastic events.
However, it is yet to be established whether there is any interaction or association between
these processes during epileptogenesis.
BBB disruption is a prominent feature in experimental and human epilepsy (Sokrab
et al., 1989; Seiffert et al., 2004). Leakage of serum-derived components into the brain
parenchyma is associated with increased excitability and the occurrence of seizures
(Seiffert et al., 2004). It was recently suggested that BBB impairment can lead to
epileptogenesis and contribute to the progression of epilepsy (van Vliet et al., 2007). Even
though BBB damage can lead to seizures and vice versa, it is yet to be demonstrated
whether this is a matter of causality or co-occurrence in epileptogenesis/ictogenesis
2.3 EXPERIMENTAL MODELS OF TEMPORAL LOBE EPILEPSY
The use of experimental animal models of TLE is with the sole aim of elucidating the
fundamental mechanisms of epilepsy essential for devising new diagnostic, therapeutic
and preventive approaches to human epilepsy. There are many epilepsy syndromes
characterized by the occurrence of one or more specific seizure type as well other clinical
features. The current challenge is producing an animal model that reproduces any given
human epilepsy syndrome. So far the use of animal models in experimental epilepsy is
limited to the study of particular aspect(s) of the epilepsy disorder.
2.3.1 Post-status epilepticus models
All post-SE animal models have in common at least three major stages: (1) the initial
episode of SE, (2) a seizure-free period of days to weeks and (3) the recurrent spontaneous
seizure stage.
11
2.3.1.1 Kainic acid (KA) Model
KA  is  a  cyclic  analogue  of  L-glutamate  and  an  agonist  of  ionotropic,  non-NMDA
glutamate AMPA and KA receptors. It is commonly administered by intraperitoneal (i.p.),
subcutaneous  (s.c.),  intravenous  (i.v.)  or  intrahippocampal  (i.h.)  injection  to  cause
sustained neuronal depolarization, SE, lasting for several hours (Nadler et al., 1978; Ben-
Ari, 1985; Longo and Mello, 1998). The receptors for KA are highest in density in the
hippocampus, especially in the CA3 region, amygdala, perirhinal and entorhinal cortices
(Miller et al., 1990). These areas are preferentially affected after KA administration and
thus KA serves as a valuable model for partial seizures with secondary generalization
(Ben-Ari, 1985; Engel, 2001).
Some of the electroencephalographic and behavioral alterations caused by KA are
similar to those observed in human patients with TLE (Lothman and Collins, 1981;
Krumholz et al.,  1995).  KA-induced  SE  models  in  rats  and  mice  also  mimic  some  of  the
neuropathological features observed in human TLE. These include loss of neurons in the
hippocampal CA1 and CA3 subfields and mossy fiber sprouting (Lothman and Collins,
1981; Okazaki et al, 1995; Sloviter, 1996; Chakravarty et al., 1997). However, neuronal
necrosis has also been reported in the piriform and olfactory cortices, amygdala, thalamus
and neocortical layers III and VI (Ben-Ari et al., 1979).
2.3.1.2 Pilocarpine Model
Pilocarpine is a muscarinic acetylcholine (Ach) receptor agonist. Systemic (i.p) injection of
pilocarpine in rats and mice produces seizures (Turski et al., 1984; Fujikawa, 2003). Its
seizure producing effect arises from the activation of muscarinic Ach receptors expressed
especially in the hippocampus, striatum and cortex (Kuhar and Yamamura, 1976). A dose
within the range of 300 to 400 mg/Kg is needed to produce SE. This very high dose
produces  significant  peripheral  effects;  thus  peripheral  muscarinic  antagonists  such  as
scopolamine methylbromide (1 mg/kg, s.c.) is used to reduce these effects.
Behavioral alterations following pilocarpine injection include facial automatism,
salivation, piloerection and behavioral automatism (Cavalheiro et al., 2006). Following
pilocarpine injection, the seizures are normally allowed to progress for at least 90 minutes
before they are stopped using diazepam to reduce mortality. The first spontaneous
epileptic seizures occur approximately 2 to 75 days after pilocarpine injection (for details
see Nissinen, 2006). Some of the neuropathological alterations are similar to that produced
by  KA.  However,  unlike  in  the  KA  model,  these  lesions  are  more  prominent  in  the
neocortex than in the hippocampus (Schmidt-Kastner and Ingvar, 1996).
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2.3.1.3 Electrical Stimulation-induced Model
This model is used less often as a model of TLE compared to KA and pilocarpine models.
However,  it  produces  clinical  signs  and  lesions  quite  close  to  those  produced  by
pilocarpine and KA models.  Induction of self-sustained SE (SSSE) is achieved by electrical
stimulation of a brain region with a 10-sec train of 1–msec square wave monophasic
stimuli at 20 Hz delivered every minute (total of 30 trains) over a period of 30 minutes
(Vicedomini and Nadler, 1987). SE is generated when the perforant path, hippocampus or
amygdala is stimulated (Mazarati et al., 2004; Bastlund et al., 2005; Tilelli et al., 2005).
The behavioral features produced by this model depend on the stimulated
structure. Some of the neuropathological findings as depicted by Nissinen and colleagues
(2000) after stimulation of the amygdala included hippocampal damage in 67% of epileptic
rats, characterized by cell loss in the hilus, CA1 and CA3 subfields of the hippocampus.
They also reported that 87% of the animals develop epilepsy within 6 months after SE. A
major  advantage  of  this  model  is  that  it  is  free  of  chemical  substances  and  the  latency
period is long compared to the KA or pilocarpine model.
2.4 THE PLASMINOGEN ACTIVATOR SYSTEM
The plasminogen activation system is an enzymatic cascade which plays an important role
in various biological processes involving extracellular matrix proteolysis. It plays two
principal roles. First, it is the central pathway for the dissolution of fibrin clots. Second, it
facilitates cell proliferation and migration by proteolytic degradation of the ECM. As such,
this system is involved in physiological processes such as development, including nervous
system development and many pathological conditions (Sumi et al., 1992). It also plays a
role in plastic events such as memory formation, neuronal death and reorganization (Meiri
et al., 1994; Wu et al., 2000). The key players in this system include plasminogen activators:
the urokinase-type plasminogen activator (uPA) and the tissue-type plasminogen activator
(tPA); the uPA receptor (uPAR), and the plasminogen activator inhibitors (PAI-1, PAI-2).
2.4.1 Plasminogen/ Plasmin
The human plasminogen is a 92-kDa zymogen composed of 791 amino acids. The amino
terminal of plasminogen includes a “finger” module and five “kringle” domains involved
in interactions with fibrin and matrix proteins. The carboxyterminal domain of
plasminogen is involved in serine protease activity (Mulichak et al., 1991). Plasminogen is
converted into a two-chain structure of plasmin by proteolytic cleavage of a single peptide
bond (Arg560Val562). Over the years, researchers have demonstrated that this cleavage is
catalyzed by uPA or tPA, as well as by certain bacterial proteins (Robbins et al., 1967).
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Plasminogen  is  expressed  in  many  tissues  of  the  body;  however,  it  is  mainly
produced in the liver and also in the testis and epidermal cells (Raum et al., 1980; Isseroff et
al., 1983; Saksela et al., 1986). It binds principally to uPA and tPA; however, it can bind to
other molecules including laminin, fibronectin, fibrin, thrombospondin, tetranectin and
cytokeratin (Quigley, 1979; Salonen et al., 1984; Lucas et al., 1983). The two principal
receptors of plasminogen include -enolase and anenexin (Miles and Plow, 1987; Hajjar et
al., 1994) and are expressed on the cell surface of various cell types including monocytes,
granulocytes, lymphocytes and endothelial cells (Hajjar et al., 1986; Silverstein et al., 1988;
Miles et al., 1987). Upon interaction with its receptors, plasminogen is rapidly converted to
plasmin which has enhanced enzymatic activity on the cell surface. However, this
proteolytic activity is regulated by the presence of uPA and tPA.
The multiple effects of plasmin activity emerge from the analysis of plasminogen-
deficient mice. These mice are able to complete embryonic development, reach adulthood
and reproduce. However, they suffer from multiple spontaneous thrombotic lesions,
organ damage, high early morbidity and impaired skin wound healing (Bugge et al., 1995;
Romer et al., 1996). This thus indicates that plasmin proteolysis is indispensable for tissue
remodeling and wound healing. In addition, the plasminogen knock-out mice model for
aplasminogenaimia, the severe form of type I plasminogen deficiency, shows few
differences in behavioural development (reactivity and response to stress) when compared
to wild type mice (Hoover-Plow J et al., 2001).
Plasminogen deficiency has also been reported in humans. It is characterized by the
formation of pseudo membranes on mucosal surfaces and often leads to organ damage of
affected tissue. The most documented and most recognizable clinical syndrome is ligneous
conjunctivitis (Schuster and Seregard, 2003). There are two types of plasminogen
deficiency in humans. Type 1, hypoplaminogenaimea, is typically associated with
pseudomembrane  formation  as  a  result  of  compromised  fibrin  clearance.  Type  II
plasminogen deficiency, dysplasminogenaemia, does not lead to specific clinical
manifestations (Shuster et al., 2001). This indicates that plasminogen deficiency does not
severely affect brain function. However, there are speculations that plasmin deficiency in
the brain could lead to Alzheimer’s disease (AD) symptomatology, possibly due to the
aggregation of amyloid, and trigger cell death signaling cascades (Dotti et al., 2004).
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Figure 2. Schematic representation of the interactions and role of uPA and uPAR as depicted
in a tumor cell. Pro-uPA is converted to uPA when it binds to uPAR. uPA then converts
planminogen (png) to plasmin,  which there on degrades the ECM. uPAR can engage in non-
proteolytic activities, independent of uPA, like signaling through GPR and integrin, and in cell
adhesion and spreading by interacting with vitronectin. Abbreviations: ECM, extracellular
matrix;  GPR,  G-protein  coupled  receptor;  MMP,  matrix  metalloprotein;  png,  plasminogen;
pngR, plasminogen receptor; suPAR; soluble urokinase-type plasminogen activator receptor;
uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator
receptor; 1, 2, 3, homologous domains of uPAR.
2.4.2 Urokinase-type plasminogen activator (uPA)
uPA is synthesized as a 53-kDA catalytically inactive single-chain polypeptide chain (pro-
uPA) with 411 amino acids (Gunzler et al., 1982). When pro-uPA is secreted, it becomes
converted to an active two-chain form, uPA, by cleavage of the peptide bond K158-I159 by
plasmin (Dano et al., 1985). Structurally, uPA is composed of two peptide chains linked by
disulfide bridges, forming three functional domains. The A chain corresponds to the non-
catalytic amino-terminal fragment (ATF), and contains the kringle domain and the
epidermal  growth  factor  (EGF)-like  domain  that  binds  to  uPAR.  The  B  chain,  which
corresponds to the carboxyl terminal region, is a serine protease domain (SPD), which is
responsible for most of its proteolytic functions (Strassburger et al., 1983; Steffens et al.,
1982).
Different  cell  types  can  synthesize  and  secrete  uPA  in  normal  conditions,  such  as
during development and pathological conditions. The first evidence of nonpathological
synthesis of uPA was demonstrated by Danø and colleagues (1985). The majority of
studies demonstrating uPA expression under pathological conditions are in cancer
research (see review by Mekkawy et al., 2009). However, increased uPA expression has
also been reported in other diseases including human and animal models of TLE (Lahtinen
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et al., 2006; Iyer et al., 2010). Its expression is linked to a variety of physiological and
pathological processes including development, wound healing, inflammation, cancer
angiogenesis and invasion (Leonardsson et al., 1995; Gyetko et al., 1996; Andreasen et al.,
1997). Expression of uPA in the brain is intense during development; however there is
limited expression in an adult healthy brain (Del Bigio et al., 1999). Expression in the adult
brain is mainly in astrocytes and neurons (Kaldron et al., 1990; Masos and Miskin, 1996;
Lahtinen et al., 2006).
uPA has proteolytic and non-proteolytic biological functions. The most
documented proteolytic action of uPA is its conversion of inactive plasminogen to
plasmin.  When  pro-uPA  binds  to  its  receptor,  uPAR,  it  is  subsequently  activated  by
plasmin  to  uPA,  which  then  converts  neighboring  membrane-bound  plasminogen  to
plasmin (fig. 2) (Stoppelli et al., 1986).  uPAR localizes pro-uPA to a specific site on the cell
surface where proteolysis is required, and as such brings about regulated degradation of
the ECM by plasmin.
The non-proteolytic functions of uPA include chemotaxis, cell adhesion and
apoptosis. When uPA binds to uPAR, it may cause cleavage of the receptor between
domain DI and DII.  This exposes the uPAR domain DII/DIII (suPAR, SRSRY) that has a
strong chemokin-like activity and sends signals through the FPRL/LXA4R receptor (fig. 2)
(Sidenius and Blasi, 2003). Also, by binding to uPAR, uPA assists in the generation of
signals via uPAR through the MEK/ERK and P13K/Akt pathways that favor the
expression of anti-apoptotic proteins of the Bcl family (fig.  2) (Alfano et al., 2006). The
activity of uPA is controlled by PAIs together with its receptor uPAR (see below).
2.4.3 Tissue type plasminogen activator (tPA)
tPA is a 70 kDa protein secreted as a precursor in the single-chain form (Pennica et al.,
1983).  It  is  converted  to  a  two-chain  active  form  by  plasmin,  with  every  single  chain
having significant activity (Neinaber et al., 1992). tPA is composed of four functional
domains: (1) an amino-terminal domain or fibronectin-like domain, (2) an EGF-like
domain, (3) two kringle regions (K1 domain and K2 domain) and (4) a serine protease
region (Pennica et al., 1983).
The main biological role of tPA is fibrinolysis. Expression of tPA is observed in
locations with close contact to fibrin clots e.g. vascular endothelial cells (Kooistra et al.,
1994). tPA is also induced in physiological situations prone to thrombosis, such as
ischemia (Schneiderman et al., 1991). However, there is interchangeability of activity
between tPA and uPA.  In studies where the tPA gene is deleted from mice, skin wound
healing proceeds normally. When both genes (tPA and uPA) are inactivated, skin wound
healing is severely impaired (Romer et al., 1996).
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In the CNS, the role of tPA is not well characterized, and its primary substrates are
even less known.  In the normal nervous system, tPA mRNA is expressed in tissue derived
from neuronal ectoderm during development (Carroll et al., 1994). In the adult nervous
system tPA was detected in the hippocampus, hypothalamus, cerebellum and amygdala
(Sappino et al., 1993; Ware et al., 1995; Hastings et al., 1997). tPA genes are induced with
neuronal activity, and their release is associated with morphologic differentiation
(Krystosek and Seeds, 1981; Qian et al., 1993), thus indicating that tPA plays a role in
synaptic plasticity. tPA has also been shown to be involved in learning and memory
(Seeds et al., 2003) as well as in behavior and anxiety (Huang et al., 1996). These
observations suggest that tPA may be involved in CNS diseases.
2.4.4 Urokinase type plasminogen activator receptor (uPAR)
uPAR is a glycosylphosphatidylinositol (GPI)-anchored protein belonging to the
lymphocyte antigen (Ly-6) super family of proteins (Ploug and Ellis, 1994). The mature
uPAR (283 residues) is highly glycosylated and composed of three homologous domains
(about 90 residues each) designated as DI, DII and DIII (Ploug, 2003; Kjaergaard et al.,
2008). The domains are connected by short linker regions, packed together forming a
concave-like structure that constitutes the binding site of its principal ligand, uPA (Huai et
al., 2006).
Under normal conditions or in a healthy organism, uPAR is thought to be
expressed to a fair degree in various tissues including the kidneys, spleen, lungs, uterus,
bladder, thymus, liver and heart (Solberg et al., 2001).  However, there is a strong
expression of uPAR in human and animal tissue undergoing extensive tissue remodeling
and in keratinocytes during wound healing (Floridon et al., 1999; Solberg et al., 2001;
Uszynski et al., 2004). Also, uPAR expression is strongly induced in various pathological
conditions including virtually all cancers (Bene et al., 2004; Jacobsen and Ploug 2008; Rasch
et al., 2008). For example, leukocyte expression of uPAR is increased during bacterial or
human immunodeficiency virus-1 (HIV-1) infections (Speth et al., 1999; Coleman et al.,
2001), in the kidneys during chronic proteinuric disease (Wei et al., 2008), in the CNS
following ischemia or trauma (Beschorner et al., 2000) and in human and animal models of
TLE (Lahtinen et al., 2009; Iyer et al., 2010; Liu et al., 2010). These findings are suggestive of
a role of uPAR in these diseases.
Generally, uPAR is known to mediate ECM proteolysis, cell- ECM adhesion and
regulate intracellular signaling pathways that control cell proliferation, differentiation,
migration and survival (fig. 2). uPAR executes its proteolytic function in conjunction with
uPA, where it promotes cell surface activation of plasminogen to plasmin (fig. 2) (Ellis et
al., 1992). uPAR is also involved in the proteolytic degradation of uPA in the lysosome, by
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the internalization of inactive complexes between uPA and PAI-1 in cooperation with
members of the low-density lipoprotein receptor (LRP) family (Cubellis et al., 1990;
Nykjaer et al.,  1992).  Many  of  the  non-proteolytic  functions  of  uPAR,  most  of  which  are
independent of the protease activity of uPA, are geared towards interactions between cells
and the ECM. By interacting functionally with matrix vitronectin (VN) (fig.  2), adhesion
receptors of the intergrin family and G protein-coupled receptors (GPR), uPAR mediates
in the migration of monocytes, melanoma, fibroblast and many other cells (Gyetko et al.,
1994; Yebra et al., 1996; Degryse et al., 1999; Madsen et al., 2007. Another non-proteolytic
function  of  uPAR  is  the  chemoattractant  property  of  its  DIIDIII  fragment  as  depicted  in
several cell lines (fig.  2) (Resnati et al., 1996). Finally, uPAR can non-proteolytically
regulate cell proliferation by interaction with integrins, resulting in downstream signals,
which activate the ERK/MAP1/2 pathways and suppress the growth inhibiting p38 MAPK
(fig.  2) (Aguirre Ghiso et al., 1999). The activity of uPAR is regulated either by cleavage
between  its  DI  and  DII  domain,  often  mediated  by  uPA,  or  by  forming  a  complex  with
uPA-PAI-1-LRP, which triggers internalization-recycling of uPAR (Cubellis et al., 1990).
uPAR  deficient  mice  are  used  to  study  the  functions  of  uPAR,  especially  in
pathological conditions including epilepsy. Though uPAR knock-out mice develop
normally, survive to adult hood and breed normally (Bugge et al., 1995), they show
defective leukocyte recruitment during infection (Gyetko MR et al., 2000), amelioration of
inflammatory proteinuria (Wei et al., 2008) and reduced brain damage in a model of
cerebral ischemia (Nagai et al., 2008). These mice also show increased susceptibility to
chemically induced seizures, heightened anxiety and reduced social interactions (Powell et
al., 2003). Recent reports suggest that mutation in one of the ligands for uPAR, Sushi-
Repeat Protein X-linked 2 (SRPX2), can cause Rolandic epilepsy with speech impairment
(RESDX syndrome) or developmental defects of the speech cortex (bilateral perisylvian
polymicrogyria) (Royer-Zemmour et al., 2008).
2.4.5 Plasminogen activator inhibitor (PAI)
Inhibitors of plasminogen activators are members of the serine protease inhibitor super
family (SERPIN). The inhibitors include PAI-1, PAI-2, and protease nexin 1 (PN1) and
protein C inactivators.
Plasminogen activator inhibitor type 1 (PAI-1)
PAI-1 is the main inhibitor of uPA and tPA. It is a single-chain glycoprotein consisting of
379 amino acids with an apparent molecular weight of 45 kDa. PAI-1 is secreted by many
cells, usually in a dormant conformation (see review Gils and Declerck, 2004). This
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conformation becomes physiologically relevant and stable by complexing with vitornectin
(Ehrlich et al., 1991).
The principal function of PAI-1 is to inhibit ECM degradation by uPA. PAI-1 forms
a complex with uPAR-bound uPA and LRP which is then internalized, engulfed by
lysosomes and digested, while uPAR is recycled to the surface (Planus et al., 1997;
Nykjayer et al., 1997). Also, when PAI-1 binds to vitronectin, it prevents vitronectin from
binding to vitronectin receptors and to 3 integrin, as such interfering with virtronectin
receptor-dependent effects such as cell migration (Stefansson and Lawrence, 1996). In a
similar way, PAI-1 can prevent vitronectin binding to uPAR (Deng et al., 1996). In fact,
PAI-1 mRNA is increased in mouse brains after a stroke (Ahn et al., 1999). PAI-1 may
protect against neuronal cell injury caused by tPA (Docagne et al., 2002).
Plasminogen activator inhibitor type 2 (PAI-2)
Human PAI-2 consists of a single chain protein with 415 amino acids and exists
predominantly as a 47 kDa nonglycosylated intracellular form or as a 60 kDa glycosylated
secreted form (Kruithof et al., 1995). Under normal conditions, PAI-2 has a limited
distribution pattern with expression detected at high levels in keratinocytes, activated
monocytes and the placenta (Sharon et al., 2001). Lower constitutive levels of PAI-2 can be
found in other cells including cells of neuronal origin (Genton et al., 1987). PAI-2 mRNA is
also localized within the nucleus accumbens (Sharon et al., 2001). Furthermore, KA
induces intense expression of PAI-2 in several brain areas including the pyramidal layer of
the hippocampus (Sharon et al., 2001).
The  role  of  PAI-2  is  not  fully  understood.  PAI-2  blocks  uPA  and,  less  efficiently,
tPA, although not as fast as PAI-1, raising the possibility that PAI-2 may have some yet
unidentified roles. PAI-2 plays a role in the skin by regulating keratinocyte proliferation
and differentiation (Hibino et al., 1999). Intracellular PAI-2 protects cells from tumor
necrosis factor- (TNF-)-medicated apoptosis (Antali et al., 1998). Monocytes and
macrophages express high levels of PAI-2 upon stimulation with tumor necrosis factor
(TNF) and lipopolysaccharide (LPS) (Suzuki T et al.,  2000).  As such, PAI-2 is involved in
monocyte differentiation (Schleuning et al., 1987). High levels of PAI-2 are present in
eosinophilic leukocytes (Swartz et al., 2004).
2.4.6 The expression and role of elements of the plasminogen system in epilepsy
Recently the role of the plasminogen activator system in neurological disorders has gained
much attention. This interest is driven by observations that this system plays a role in the
normal brain and in many brain pathologies including experimental models of seizures
and epilepsy (Gingrich and Traynelis, 2000; Yepes and Lawrence, 2004; Melchor and
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Strickland, 2005; Yepes et al., 2009). Different elements of the system are linked to
neurodegeneration, axonal plasticity and seizure threshold, even though the mechanisms
by which they alter these events remain unclear.
Plasminogen
Plasmin, produced by proteolytic cleavage of plasminogen either by uPA or tPA, has
several substrates in the brain, including ECM proteins (Benarroch, 2007). Tsirka et al.
(1997) showed plasminogen mRNA expression in most hippocampal neurons, with
minimal expression of the protein in just a fraction of the cells. In addition, they showed
that intrahippocampal injection of kainate induces increased hippocampal expression of
plasminogen.
uPA
uPA  mRNA  is  one  of  the  most  upregulated  genes  in  animal  models  of  TLE  including
angular bundle stimulation and amygdala stimulation models on rats (Lukasiuk et al.,
2003; Lahtinen et al., 2006; Gorter et al., 2007). Lahtinen et al. (2006) showed using the
electrical stimulation SE model that increased mRNA expression is accompanied by
increased uPA enzymatic activity in the hippocampus and extrahippocampal temporal
lobe.  They further reported that expression was prominent in small populations of
astrocytes,  neurons  and  blood  vessels.  A  similar  finding  was  previously  reported
following KA-induced SE (Masos and Miskin, 1997). Increased uPA mRNA expression is
observed in neurons, astrocytes, microglia and blood vessels in humans with epilepsy
(Iyer et al., 2010). The effects of increased uPA expression on the epileptogenic network are
not clearly understood. However, Morales and colleagues (2006) showed that uPA
knockout mice developed significantly larger lesion volumes than wild-types following
TBI, indicating a possible role of uPA in neuroprotection.
tPA
tPA was first shown to be linked to epilepsy by Qian et al. (1993). They showed increased
tPA expression in rat cortexes following pentylenetetrazol (PTZ) induced seizures. Also,
there is an increase in tPA mRNA expression in the hippocampus following perforant path
stimulation and intrahippocampal injection of kainate (Qian et al., 1993; Salles and
Strickland, 2002). In human epilepsy, there is increased tPA expression in tissues from
patients with gangliogliomas but not in those with TLE without hippocampal sclerosis or
focal cortical dysplasia (Iyer et al., 2010). Increased tPA mRNA expression is tied with an
increase in tPA enzymatic activity after intraamygdala or intraventricular KA injection
(Endo et al., 1999; Yepes et al., 2002).
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The effect of tPA on seizure susceptibility was revealed using tPA knock-out mice.
Tsirka et al. (1995) showed that tPA deficient mice require a higher dose of KA or PTZ to
enter seizures compared to controls. Similarly, tPA deficient mice showed decreased
seizure progression and lacked generalized seizures following intra-amygdala KA
injection (Yepes et al., 2002). These effects were shown to be plasminogen-independent
(Yepes et al., 2002). Various mechanisms have been proposed to be involved in the
facilitation  of  seizures  by  tPA,  including  the  cleavage  of  the  NR1  subunit  of  NMDA
receptor by tPA in cortical neurons (Benchenane et al., 2007).
uPAR
It was recently demonstrated using the amygdala stimulation SE model that, uPAR
mRNA expression is increased at 1-4 days after SE (Lahtinen et al., 2009). Lahtinen and
colleagues showed that uPAR protein expression levels lasted 2 weeks after SE and were
mostly concentrated in astrocytes, neurons and in parvalbumin positive interneurons in
the hippocampus and dentate gyrus, and in a subgroup of somatostatin and neuropeptide
Y positive hilar interneurons. However, in normal brains, expression was limited only to
astrocytes and to a limited number of parvalbulmin-positive interneurons.
There is also uPAR mRNA expression in TLE patients with hippocampal sclerosis
and focal cortical dysplasia, as well as in patients with frontal lobe epilepsy (Iyer et al.,
2010; Liu et al., 2010).  uPAR expression is mostly in neurons and very few astrocytes (Liu
et al., 2010).
The role of uPAR in epilepsy was recently highlighted by observations made by
Powell and colleagues (2003) using uPAR knock-out mice. They showed that uPAR
deficient mice were susceptible to chemically induced seizures, and had poor social
interactions. In addition, they linked these observations to poor interneuron development,
particularly of the parvalbumin subtype.
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Table 1. Experimental studies describing behavioural and pathological changes associated with
uPA and uPAR after brain damaging insults.
Model/ animal Finding Reference
FCI infarction in
mice
 No difference in infarct size 24h after injury  between
uPA-/- and Wt
 Nagai et al.,
1999
Severe malaria in
mice
 No difference in BBB impairment between uPAR-/- and
Wt.  Absent of macrophage sequestration in uPAR-/-
 Piguet et al.,
2000
Brain stab wound
in mice
 Similar levels of BBB impairment  in uPA-/- and Wt at
3, 8, and 15 days after injury
 Kataoka et al.,
2000
Experimental
pneumococcal
meningitis in mice
 Attenuated CSF pleocytosi in uPAR-/- at 24h post-
injury. No difference in BBB impairment, intracranial
pressure and chemokine
 Paul et al.,
2005
TBI (CCI model ) in
mice
 Increase size of lesion in uPA-/-  Morales et al.,
2006
TBI and focal
cerebral infarction
in humans
 Increase number of uPAR expressing granulocytes,
microglia/ macrophages and endothelia cell, correlated
with increase edema
 Beschorner et
al., 2000
Fluid percussion
injury in pigs
 At 4 hr post-injury, uPA expression is associates with
age dependent  hyperaemia
 Armstead et al.,
2009
uPA over
expression in mice
 Decrease food consumption, reduced body weight and
size
 Miskin and
Masos, 1997
uPA over
expression in mice
 Impaired learning  Meiri et al.,
1994
uPAR-/- mice  Disruption of GABAA receptor subunits; alfa 1, 2 and
3, Beta 2 and 3, and gamma 2S and 2L in frontal and
parietal cortices
 Eagleson et al.,
2010
PIFBD and MCAO in
mice
 Smaller lesion is uPAR-/- compared to Wt at 3 d post-
MCO, whereas no difference with Wt in PIFBD injury
 Nagai N et al.,
2010
MCAO in mice  Decreased  brain  damage  in  uPAR-/-  mice  at  3  d  post
injury
 Nagai N et al.,
2008
EAE in mice  uPAR-/- mice experienced  delayed less acute disease
which subsequently become chronic
 East et al.,
2005
Cortical
development in
uPAR-/-  mice
 P21 uPAR-/- mice showed loss of cortical GAD67 and
GABA positive cells. Only loss of cortical parvalbumin
cells in adults.
 Eagleson et al.,
2005
uPAR-/- mice
(naïve animals)
 Increase anxiety, spontaneous seizures and increase
susceptibility to PTZ-induced seizures. 50% loss of
GABAergic interneuron especially parvalbumin subtype
in anterior cingulated and parietal cortices
 Powel et al.,
2003
Abbreviations:  BBB,  blood  brain  barrier;  CCI,  control  cortical  impact;  d,  day;  EAE,
experimental allergic encephalomyelitis; FCI, Focal cerebral ischemic; GAD67, glutamic acid
decarboxylase-67; hr, hour; i.h., intrahippocampal; KA, kainic acid; P, post-natal; PIFBD,
photochemical  induced  thrombotic  brain  damage;  PTZ,  pentylenterazole;   MCAO,  medial
cerebral artery occlusion; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type
plasminogen activator; Wt, wild type.
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3. Aims of the study
The broad objective of this study is to increase our understanding of the interactions and
functional implications of the cellular and molecular reorganization processes known to
occur during epileptogenesis. Furthermore, it aims to study the underlying molecular
mechanisms involved in these cellular reorganization processes.
Therefore, the specific aims of this work are to:
1. Study the interaction between vascular remodeling and neuronal plasticity during
epileptogenesis
2. Study  the  functional  implications  of  blood  vessel  length  changes  in  the
hippocampus during epileptogenesis
3. Determine whether uPA or uPAR deficiency differentially affect the epilepsy
phenotype following an epileptogenic insult such as status epilepticus
4. Decipher the role of uPA and uPAR in the cellular reorganization processes during
epileptogenesis
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4. Materials and methods
4.1 ANIMALS
All animal experiments were approved by the Animal Care and Use Committee of the
University of Eastern Finland. All procedures were conducted in accordance with
guidelines set by the European Community Council Directives 86/609/EEC. Animals were
housed in a control environment (temperature 22°C ± 1°C, humidity 50-60%, lights on
07:00-19:00) with free access to water and food.
Rats (I)
Adult male Sprague-Dawley rats (Harlan, the Netherlands) weighing 300-350g housed in
individual cages were used.
Mice (II, III)
For study II, Adult male mice (12-14 weeks) lacking the uPA gene in C57BL/6 background
(uPA-/-; B6.129S2-Plautm1Mlg/J from The Jackson Laboratory, Bar Harbor, USA; Carmeliet et
al., 1994) and their wild type (Wt) littermates were used.
For study III, adult male mice (12-14 weeks) lacking the uPAR gene (uPAR-/-, B6.129P2-
Plaurtm1Jld,  a  generous  gift  from  Dr.  Van  der  Pol,  University  of  Amsterdam,  The
Netherlands) were used. uPAR-/- mice were backcrossed to C57BL/6 genotype (Charles
River, originally JAXC57BL/6J Stock 000664 from The Jackson Laboratory) for at least 8
generations. The genotype of mice in all studies was determined by PCR.
4.2 ANESTHESIA
Rats
For MR imaging, animals were anesthetized with isoflurane in a carrier gas mixture of
70% N2O, 30% O2. For transcardiac perfusion, animals were anesthetized with 6 ml/kg,
(i.p.) of an anesthetic cocktail containing 58 mg/kg sodium pentobarbital and 60 mg/kg
chloral hydrate.
Mice
For the induction of status epilepticus, implantation of cortical and/or hippocampal
electrodes and transcardiac perfusion, animals were anesthetized with a mixture of 18.75
mg/ml ketamine and 0.25 mg/ml medetomidine (4 ml/kg, i.p.).
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4.3 INDUCTION OF STATUS EPILEPTICUS (SE)
4.3.1 Pilocarpine model (I)
Animals  were  injected  subcutaneously  (s.c.)  with  scopolamine  (1  mg/kg;  #S-8502,  Sigma
Chemical Co., St. Louis, MO) to reduce the peripheral adverse effects of pilocarpine. Thirty
minutes later, SE was triggered by intraperintoneal (i.p.) administration of pilocarpine
(320 mg/kg, #P-6503, Sigma Chemical Co., St. Louis, MO). The development and severity
of generalized SE was assessed by visual observation, and the behavioral severity of
seizures during SE was scored according to Racine (1972). Diazepam 20 mg/kg (i.p.,
Stesolid Novum, Dumex-Alpharma) was administered 120 minutes following induction of
SE to reduce the mortality rate. Control animals were treated similarly except they were
injected with 0.9% NaCl instead of pilocarpine
4.3.2 Intrahippocampal kainic acid model (II, III).
Animals were anesthetized and placed into a stereotactic device. The skull was exposed
and a small hole was drilled at the injection site. Using a glass pipette (inner diameter 0.2
mm; outer diameter 0.75 mm; tip diameter 0.01-0.02 mm) connected to a pulse pressure
device (Picospitzer, General Valve Corporation, Fairfield, USA), 60 nl of 20 mM (II) or 10
mM (III) of KA or 0.9% of NaCl (controls) was injected into the right hippocampus with
coordinates AP-2.3; ML-1.5 (bregma as reference, mouse atlas of Franklin and Paxinos,
2008) and DV 1.9 below dura. After injection, the capillary was kept in place for 5 minutes
and then withdrawn slowly (100 μm at a time, 20-30 sec intervals). The aim was to get the
injection into the dentate gyrus. After the operation, the mice were injected with
Antisedan (0.5 mg/kg i.p; antipamezole hydrochloride; Orion Pharma, Espoo, Finland)
and 0.9% saline (150μl/animal) to facilitate awakening from anesthesia.
4.4 ELECTRODE IMPLANTATION
4.4.1 Cortical electrodes (II, III)
Following intrahippocampal kainate injection, four cortical screw electrodes were
implanted. Two electrodes were placed bilaterally into the skull above the parietal cortex
(AP -1.10; ML 2.5 with bregma as reference). The other two were placed bilaterally over
the cerebellum to serve as ground and reference electrodes.
4.4.2 Hippocampal electrodes (III)
After kainate injection, a bipolar nylon-coated stainless steel wire electrode ( 0.127 μm;
dorsoventral tip separation 400 μm, Franco Corradi, Milan, Italy) connected to a gold-
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plated pin (Plastics One Inc., Roanoke, VA, USA) was implanted into the brain. The lower
electrode  tip  was  aimed  to  hit  the  suprapyramidal  blade  of  the  granule  cell  layer  in  the
dentate gyrus (AP -2.3 ML -1.5, DV -1.9).
Electrodes were secured in place with dental acrylate (Selectaplus CN, Dentsply
DeTrey GmbH, Dreieich, Germany). After the operation, animals were injected with
Antisedan (0.5 mg/kg i.p; antipamezole hydrochloride; Orion Pharma, Espoo, Finland)
and 0.9% saline (150 μl/animal) to facilitate awakening from anesthesia.
4.5 VIDEO-EEG MONITORING (II, III)
After the implantation of cortical and/or hippocampal electrodes, animals were moved to
their  home  cages,  connected  to  the  video-EEG  recording  system,  and  continuously
monitored for 30 d (24/7) as previously described by Nissinen et al. (2000). An infrared
sensitive camera and infrared light were placed in front of the cages. Infrared light
permitted video monitoring of animal behavior during the dark cycle.  A wide-angle lens
permitted digital video-recording of up to 8 animals at the same time.
4.5.1 Detection and analysis of severity of status epilepticus (II, III)
After the induction of SE, electrographic activity was recorded using a video-EEG
recording system from Nervus (Taugagreining, Iceland). The severity of status epilepticus
was assessed by counting the total number of spikes generated in EEG during the first 48
hours after KA administration, using Clamfit 9.0 software according to Pitkänen et al.
(2005). A spike was defined as a high amplitude discharge (> 2x baseline) lasting less than
70 ms.
4.5.2 Detection and analysis of electrographic and behavioral seizures (II, III)
The development of spontaneous seizures was studied using data from the video-EEG
recording system. Seizures were analyzed by manually browsing through all EEG data
files on a computer screen with the aid of the Nervus® EEG reader software. An
electrographic seizure was defined as a high-frequency (> 5 Hz), high-amplitude (> 2x
baseline) discharge lasting for more than 10 s. When an electrographic seizure was found,
its behavioral severity was analyzed from the matching video recording. Behavioral
seizure activity was scored according to a slightly modified Racine's scale (Racine, 1972):
score 0, electrographic seizure without any detectable motor manifestation; score 1, mouth
and face clonus, head nodding; score 2, clonic jerks of a forelimb; score 3, bilateral forelimb
clonus;  score  4,  forelimb  clonus  and  rearing;  score  5,  forelimb  clonus  with  rearing  and
falling.
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4.6 BrdU ADMINISTRATION FOR STUDY OF ENDOTHELIAL CELL
PROLIFERATION (I)
To investigate the proliferation of endothelial and neuronal cells after SE, animals were
injected with 5-bromo-2'-deoxyuridine (BrdU) dissolved in 0.9% NaCl (BrdU, 50mg/kg,
#280879, Roche Diagnostics Corp., Indianapolis, IN) twice a day (i.p.) at an interval of 12 h
for 5 d. The last injection was administered 24 h before sacrifice.
4.7 MAGNETIC RESONANCE IMAGING MEASUREMENT OF CEREBRAL
BLOOD FLOW (CBF) AND CEREBRAL BLOOD VOLUME (CBV) (I)
To assess the functional consequences of observed vascular changes, MRI was employed
to measure absolute CBF and relative CBV in the rat hippocampus. Rats were anesthetized
and  cannulae  were  inserted  into  the  femoral  vein  and  femoral  artery,  for  contrast  agent
delivery and arterial blood sampling to monitor blood gases, respectively. The rat was
secured in a stereotactic holder using ear bars and a bite bar. Breath rate was continuously
measured throughout imaging via a pressure probe between the rat and the holder. The
breathing rate measurement helped us to control the anesthesia concentration, which was
maintained at 0.7-1.7%. The holder was electronically heated to sustain a temperature of
37°C throughout.
All MRI was performed using a 4.7 T scanner (Magnex Scientific Ltd, Abington,
UK) interfaced to a Varian Inova console (Varian, Palo Alto, CA) with an actively
decoupled linear transmission volume coil and quadrature surface receiver coil pair
(Rapid Biomedical, Germany). CBF was quantified using continuous arterial spin labeling
(Williams et al., 1992) (duration of labeling pulse = 3 s, B1 = 0.018 mT, 800 ms delay after
labeling pulse) with a fast spin echo read out (field of view = 4 x 4 cm, 128 x 128 points, 2
mm slice thickness, repetition time = 6 s, 16 echoes/excitation, echo spacing = 7 ms, 6 pairs
of label and control images) from one coronal hippocampal slice. Absolute CBF was
calculated in the hippocampus through region of interest (ROI) analysis of CBF maps
generated by the arterial spin labeling approach. CBF maps were corrected for T1 variation
across the brain by employing a T1 inversion recovery, fast spin echo sequence to provide
T1 maps that were incorporated into CBF map calculations (Barbier et al., 2001). The
sequence parameters were as follows: field of view = 4 x 4 cm , 64 x 64 points, 2 mm slice
thickness, repetition time = 5 s, echo spacing = 6 ms, inversion times = 5, 300, 600, 1000 and
1500 ms.
R2 was mapped by acquiring T2 weighted images (field of view = 4 x 4 cm, 256 x
128 points, echo time = 70 ms, repetition time = 2500 ms, 15 coronal slices, 1 mm slice
thickness) taken before and 3 min after iron oxide contrast agent injection (Sinerem,
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Geurbet, France) at 6 mg/kg rat body mass. R2 caused by the intravascular contrast agent
was assumed to be directly proportional to CBV (Dunn et al., 2004), which was quantified
in the hippocampus and dorsal cortex from a single hippocampal R2 map. The CBF map
and chosen CBV map were from an identical slice. Hippocampal CBV was normalized to
that of the healthy neck muscle in order to account for contrast agent concentration
variations between animals, hence relative CBV was studied. Arterial blood pH, pCO2 and
pO2 were monitored by blood sampling before contrast agent injection, around 60 min
after cannulae surgery, and again soon after imaging was completed. The total imaging
time was around 100 min per animal. After imaging, rats received recovery surgery to
remove the cannulae.
4.8 PROCESSING OF BRAIN FOR HISTOLOGY
4.8.1 Transcardiac perfusion - Timm fixation protocol (I, III)
Timm fixation was carried out according to Sloviter (1982). Briefly, animals were deeply
anesthetized and perfused transcardially with 0.37% sulfide solution for 10 min using
peristaltic pump followed by cold (4°C) paraformaldehyde (PFA) in 0.1 M sodium
phosphate buffer (PB, pH 7.4) for 10 min (flow rate, Rats: 30 ml/min; Mice: 5 ml/min).
After  perfusion  the  brains  were  removed  from  the  skull,  postfixed  in  4%
paraformaldehyde in 0.1 M PB at 4°C for 4 h, cryoprotected in 20% glycerol in 0.02 M
potassium phosphate-buffered saline (KPBS) at 4°C for 24 h, frozen on dry ice, and stored
at -70oC.
4.8.2 Transcardiac perfusion - Para-formaldehyde fixation protocol (I-III)
Animals were deeply anesthetized and were transcardially perfused with 0.9% NaCl (2
min)  followed by 4% paraformaldehyde in  0.1  M in  PB (Rats,  30  min and mice,  20  min).
After perfusion, the brains were further processed as described above in the Timm
perfusion protocol.
4.8.3 Sectioning of brain
The  brains  were  cut  serially  in  the  coronal  plane  using  a  sliding  microtome.  For  rats,
sections were cut 30 μm thick in a 1-in-5 series. For mice, sections were cut 25 μm thick in
a 1-in-6 series. The first series of sections was stored in 10% formalin and the other series
of sections were stored in a cryoprotectant tissue collecting solution (30% ethylene glycol
and 25% glycerol in 0.05 M PB) until further processed.
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4.9 HISTOLOGY
4.9.1 Nissl staining and analysis of neuronal damage (I - III)
In order to identify the distribution and severity of neuronal damage, the first series of
sections (stored in 10% formalin) were stained using thionin, cleared in xylene, and cover-
slipped using DePeX (BDH Chemical, Poole, United Kingdom) as a mounting medium.
4.9.1.1 Analysis of damage to principal cells (I, II, III)
Neuronal damage in the CA1 and CA3 subfield of the hippocampus was estimated from
nissl stained sections, using a semiquantitative scoring method. Severity of degeneration
was scored according to Freund et al. (1992) as follows: 0 = no cell loss, 1 = less than 20% of
neurons lost, 2 = 20 to 50% of neurons lost, 3 = over 50% of neurons lost. Eight consecutive
sections from the level at which suprapyramidal and infrapyramidal blades of the granule
cell layer become fused together were analyzed, blind to the experimental groups. The
severity of neurodegeneration in each subfield in each section was scored, and the mean
score was used for statistical analysis.
4.9.1.2 Analysis of damage to hilar cells (II, III)
Damage to dentate hilar cells was estimated bilaterally using unbiased stereology.
Systematic sampling of nissl-stained sections with a random start, covering the entire
septotemporal axis of the hippocampus, was employed. Sampling was started at the level
where the supra and infra-pyramidal blades of the hippocampus fuse together. For mice, a
section sampling fraction of 1:12 was used. Sections were analyzed using
StereoInvestigator software (Version 2006, MicroBrightField Inc., Colchester VT,
Germany) under an Olympus BX50 microscope equipped with a motorized stage
interfaced with a Hitachi HV-C20A camera. The total number of hilar cells was estimated
using the optical fractionator method (West et al., 1991). The region of interest was
outlined at  low magnification and a  sampling grid of  40  μm (x-axis)  and 40  μm (y-axis)
was placed on the section. For each x–y step, cell counts were derived from a known
fraction of 28 μm (x-axis) by 28 μm (y-axis) (an "optical dissector"). Counting was
performed throughout the section and the total number of hilar cells was estimated using
the following equation: Ntot = Q · 1/ssf · 1/asf · 1/tsf, where ssf is section sampling fraction,
asf is area sampling fraction (the area of the counting frame divided by area of sampling
grid), and tsf is tissue sampling fraction (the height of the mounted section thickness
divided by the dissector height).
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4.9.1.3 Analysis of granule cell layer volume (II, III)
To determining the extent of granule cell  layer dispersion post-SE in mice following KA-
injection, granule cell layer volume was measure bilaterally from nissl stained sections
using unbiased stereology. The volume was estimated using Cavalieri principle. A similar
sampling scheme as described for hilar cell count in mice was employed. After delineating
the region of interest (ROI) at low magnification, a grid of 100 μm (x-axis) by 100 μm (y-
axis)  was  laid  on  the  section.  The  total  number  of  hit  points  within  the  selected  area  of
interest was counted as described by Gundersen and Jensen (1987).  The volume of the
granule cell layer was calculated using the formula: V = Pi · a(p) · T, where P is the total
number of hit points counted in all sections, a(p) is the area associated per point (0.01
mm2), and T is the section thickness (300μm, ssf multiplied by section thickness).
4.9.2 Timm histochemistry and assessment of mossy fiber sprouting (I, III)
To be able to assess post-injury synaptic reorganization in the dentate gyrus, one series of
sections (Timm-fixed) were stained using Timm sulfide/silver method as previously
described by Sloviter, 1982.
Assessment of mossy fiber sprouting
Density of mossy fibers was assessed in the supragranular region and inner molecular
layer of the dentate gyrus. Analysis was performed along the septotemporal axis of the
hippocampus, starting at the level were the suprapyramidal and infrapyramidal blade of
the  granule  cell  layer  form  a  continuous  band  of  cells.  In  rats, analysis was performed
separately from the "tip", "mid" and "crest" portions of the granular cell layer as described
before (Nissinen et al., 2001) using a semiquantitative scoring scale according to Cavazos et
al. (1991) (for details see Nissinen et al., 2001). In mice, only the contralateral dentate gyrus
was analyzed since sprouting was absent in the severely damaged ipsilateral side
following kainate injection. The analysis in mice was performed using National Institute
for Health (NIH) ImageJ® software version 1.45b. First, a digital photomicrograph was
captured from each section using a Leica DMRD microscope at 5x objective. The area
including the supragranular region and inner molecular layer of the dentate gyrus was
delineated. The image was then converted to grayscale and threshold to match with the
staining (Buckmaster and Lew, 2011). Thereafter, the area (Ai) covered by the mossy fibers
within the delineated area was automatically calculated. The total volume (V) was
calculated using the formula: V = Ai · T · n, where Ai is the sum of areas from n sections,
T is the section thickness and n is the number of sections sampled.
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4.9.3 Doublecortin (DCX) immunohistochemistry and analysis of neurogenesis (I-III)
In order to be able to assess post-injury neurogenesis in the dentate gyrus, sections were
stained for doublecortin (DCX). Free floating sections were washed (0.02 M KPBS) and
incubated for 15 min in 1% H2O2 in KPBS to remove endogenous peroxidase activity. Then
were rinsed 6 times with 0.02 M KPBS and non-specific binding was blocked in a solution
containing 10% normal horse serum (NHS), 0.4 % Triton X-100, and KPBS at RT for 2 h.
This was followed by incubation in goat-derived anti-doublecortin antibody (1:800; SC-
8066; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in 1% NHS and 0.4% Triton X-100
in KPBS at 4°C overnight.  Sections were washed (2% NHS, prepared in 0.02 M KPBS) and
incubated in a secondary antibody solution containing biotinylated horse anti-goat IgG
(1:300; BA-9500; Vector laboratories), 1% NHS, and 0.4% Triton X-100 in KPBS for 2 h at
RT. After washing (0.02 M KPBS) they were further incubated in 1% avidin-biotin (PK-
4000; Vector Laboratories) in KPBS for 1 h at RT. Then were washed (0.02 M KPBS) and
recycled back to the secondary antibody solution for 45 min, and then to the avidin-biotin
solution  for  30  min.  The  secondary  antibody  was  visualized  by  incubating  in  a  solution
containing 0.05% DAB (Pierce Chemical) and 0.04% H2O2 in KPBS for 2 min at RT.
Analysis of neurogenesis
To estimate total number of DCX-positive cells, the optical factionator method was used
with the aid of the stereoinvestigator software as described above for hilar cells. In rats,
analysis  was  performed  in  the  whole  dentate  gyrus.  A  section  sampling  fraction  (ssf)  of
1:15 was used and cells were counted with an x-y step of 100 μm by 100 μm and a
counting frame of 22 μm by 22 μm.
In mice, in addition to the entire dentate gyrus, analysis was performed in the three
separate areas; hilus, subgranular zone and granule cell layer. Sampling was performed as
described above for hilar cells. An x-y step of 40 μm by 40 μm and a counting frame of 19
μm by 19 μm were used. The total number of DCX- positive cells was estimated using
same formula as described for hilar cells.
4.9.4 IgG immunohistochemistry and analysis of blood-brain barrier damage (I, III)
In order to investigate post-SE disruption of blood-brain barrier (BBB) sections were
immmuno-stained for IgG leakage into the brain. First, sections were washed and
endogenous peroxidase was removed as described for DCX staining.  In rats, sections
were subsequently incubated in a rabbit-derived biotinylated anti-rat IgG antibody (1:200;
#BA- 4000, Vector laboratories) and in mice in horse-derived anti-mouse IgG antibody
(1:300, BA2000, Vector Laboratories) prepared in a solution containing 4% NHS and 0.4%
Triton-X100 at 4°C overnight. Subsequently, sections were washed (0.02 M KPBS) and
incubated in a solution containing avidin-biotin-complex prepared according to
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instructions provided by the manufacturer, for 1 h. The peroxidase activity was visualized
as described for DCX staining but incubated for 1 min.
Quantification of blood-brain barrier damage
The  magnitude  of  BBB  damage  was  quantified  by  measuring  the  intensity  of  IgG
immunoreactivity in stained hippocampal sections by using the NIH ImageJ® software.
Briefly, digital photomicrographs of the hippocampus were captured using Leica DMRD
microscope at 5x. The ROI was outlined, the image was converted to gray scale,  and the
gray scale value corresponding to relative optical density (ROD) (immunoreactivity) of the
IgG staining was measured. In rats, the background value was measured from the
undamaged region of the corpus callosum and for mice, the thalamus. In rats, the degree
of IgG leakage was calculated as a ratio of the mean hippocampal grey scale value to that
of the corpus callosum. In mice, IgG reactivity was calculated as the difference between
measure ROD in the ROI and background staining in the thalamus.
4.9.5 Thrombosis immunohistochemistry and assessment of thrombocyte (I)
To study the formation of thrombus post-SE, free floating sections were immunostained
for thrombus. The protocol was essentially same as for DCX staining except the primary
antibody was a rabbit-derived antibody raised against rat thrombocyte (1:1000, #
CLA41440, Cedarlane laboratories, Hornby, Ontario, Canada) and the secondary antibody
was biotinylated goat-derived antibody raised against rabbit-IgG (1:200; #BA-100, Vector
laboratories). Antigen was visualized using Vector VIP substrate kit (#SK-4600, Vector
laboratories) according to instructions provided by the manufacturer.
Assessment of thrombocyte formation
The  total  number  of  thrombi  was  analyzed  from  consecutive  sections  from  the  septal
hippocampus (1-in-5, 150 m apart from each other), beginning at the level where the
suprapyramidal and infrapyramidal blades of the granule cell layer form a continuous
band of cells [-3.3mm posterior from bregma, Paxinos and Watson (1998)]. Using the
StereoInvestigator software, a grid of dimension 400 μm (x) by 400 μm (y) was laid on the
section and a counting frame of 20 μm by 20 μm was used to count the thrombi. The total
number of thrombi was estimated by multiplying the total number of counted thrombi
from the 3 sections by the area sampling fraction (asf) [Ntot = Q · 1/asf] (where Q is the
total number of counted thrombi).
4.9.6 CD68 immunohistochemistry and assessment of macrophage response (III)
To evaluate the effect of an injury-induced macrophage response, sections were stained for
CD68, which is a lysosomal marker in phagocytotic macrophages. The protocol was
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essentially the same as for DCX staining except the primary antibody was a rat-derived
anti-mouse CD68 antibody (1:500, MCA 1957, Serotec) and the secondary antibody a
rabbit-derived biotinylated anti-rat IgG antibody (1:300, BA4001, Vector Laboratories).
Assessment of macrophage response
Section sampling for analysis was performed as previously described for mice hilar cells
analysis. To study the progression of CD68 reactivity a time course analysis was
performed at 4 d and 30 d post-SE. Analysis was first performed in the entire
hippocampus, and then, separately in the CA1 and CA3 subfields of the hippocampus
proper and the hilus of the dentate gyrus. Quantification of immunoreactivity was done
by  using  NIH  ImageJ®  software  as  described  for  IgG  (see  above).  In  addition,  CD68
immunoreactivity in extra-hippocampal regions (amygdala and hypothalamus) was
analyzed using a semiquantitative scoring scheme. Scoring was done as follows: 0 = no
reactivity, 1 = very weak reactivity, 2 = weak reactivity, 3 = moderate reactivity, and 4 =
strong reactivity.
4.9.7 CD3 immunohistochemistry and assessment of T cell response (III)
To further assess the inflammatory response post-SE, sections were stained for CD3, a
marker for T-lymphocytes. A similar staining protocol as described for DCX staining was
employed, except that the primary antibody was a hamster-derived anti-mouse CD3
antibody (1:1000, #553058, BD Pharmingen) and the secondary antibody was a goat-
derived anti-hamster IgG (1:300, BA9100; Vector Laboratories).
Assessment of T cell response
The total number of CD3-positive cells was estimated in the ipsilateral CA1 and CA3
subfields of the hippocampus, and the hilus of the dentate gyrus, with the aid of the
StereoInvestigator software. The contralateral hippocampus was not included in the
analysis  due  to  the  relatively  sparse  number  of  T-lymphocytes  observed.  A  similar
sampling scheme as described earlier for the estimation of the total number of hilar cells in
mice was employed. The number of immunopositive T-cells in each region of interest was
counted. The number of cells per mm3 (T) was estimated using the formula: T = Q /Ai · 12
· 0.025, where Q is the total number of cells (Q) counted in all sections, Ai is the sum of
areas of ROIs (mm2), 12 is the sampling fraction, and 0.025 is the section thickness (mm).
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4.9.8 Blood vessel immunohistochemistry (I, II, III)
4.9.8.1 Rat endothelial cell antigen-1 (RECA-1) and endothelial barrier antigen (EBA)
immunohistochemistry (I)
To study the vascular morphometry and spatiotemporal evolution blood vessels post-SE
in rats, sections were immune-stained with either mouse derived anti-rat EBA (SMI71, 1:10
000; Sternberger Monoclonals Inc; Baltimore, MD) or mouse derived anti-RECA-1 (1:5000;
#MCA970R, Serotec, Oslo, Norway) as primary antibodies. A biotinylated horse-derived
anti-mouse IgG (1:200; #BA-2000, Vector Laboratories, Burlingame, CA, U.S.A.) was used
as  the  secondary  antibody.  The  protocol  was  basically  the  same  as  described  for  DCX
staining.
4.9.8.2 Lycopersicon esculentum (tomato) lectin staining (II, III)
Biotinylated Lycopersicon esculentum (tomato) lectin (1:1000; B-1175; Vector Laboratories,
Burlingame,  CA,  USA)  was  used  to  visualize  blood  vessels  in  mice  brain  sections.  The
protocol was essentially the same as described for IgG staining.
4.9.8.3 Assessment of total blood vessel length (I, II, III)
The total blood vessel length was estimated using unbiased stereology with the aid of
stereoinvestigator® software. The virtual sphere method (Mouton et al., 2002) was used. A
three-dimensional sampling hemisphere (“space ball”) of known radius and height was
placed in a box of known dimensions and focused through the section thickness.  For
every x-y step, the number of vessels intersecting the sphere was counted with the aim of
generating counts of about 300 intersections per animal.
In rats, the total blood vessel length was estimated unilaterally (left hippocampus)
in the CA1 and CA3 subfields of the hippocampus and the molecular layer of the dentate
gyrus. Every third section from a 1-in-5 series was used (ssf = 1/15). A sampling
hemisphere ("space ball") with a radius of 20 μm and height of 10 μm was placed within a
sampling box of known dimensions (x = 69.5 μm, y = 69.5 μm and z = 10 μm). The x-y
steps giving the distance between sampling areas was 400 μm (x-axis) by 400 μm (y-axis).
In order to calculate the total length of blood vessels, the following equation was used: Ltot
= Q · 2 · 1/ssf · 1/asf · 1/tsf · [v/a], where ssf is 1/15, asf is 0.03, tsf is 1, and v/a 19.2 μm
[defined as the ratio of the volume of the counting frame (v) (sampling box) to the surface
area of the hemisphere probe].
In mice, the total blood vessel length was estimated bilaterally using a similar
sampling scheme as described for hilar cell count in mice. A hemisphere probe of diameter
20 μm and height 10 μm was placed within a counting frame 40 μm wide (x-axis), 40 μm
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high (y-axis), and 10 μm deep (z-axis). An x-y step of 300 μm (x-axis) by 300 μm (y-axis)
was used. The total blood vessel length was estimated using the same formula as
described above for rats.
4.9.8.4 Assessment of Blood vessel diameter (I)
Blood vessel diameter was measured in sections stained for RECA-1. Every third section
from a 1-in-5 series was sampled (ssf = 1/15). The hippocampal fissure was analyzed
separately. The analysis was performed using the StereoInvestigator® software. A grid of
380 μm (x) by 380 μm (y) (hippocampus) and 150 μm (x) by 150 μm (y) (for hippocampal
fissure) was superimposed on the section. A counting frame (40 μm x 40 μm) was used in
the analysis. The diameter of all vessels within the counting frame was measured using
the “quick line” measurement tool.
4.9.9 BrDU-RECA-1 double staining and analysis of endothelial cell proliferation (I)
Double staining of BrdU-positive cells and blood vessels with RECA-1 permitted the study
of newly formed blood vessels post-SE. First, free-floating sections were treated with 2 M
HCl for 30 min at 37°C to denature DNA (enabling BrdU to be labeled), and after that
washed with 0.1 M boric acid (pH 8.5) to remove residual acid. The subsequent part of the
protocol  is  essentially  the  same  as  that  used  for  DCX  staining  except  that  two  primary
antibodies were used, mouse-derived anti-RECA-1 (1:5000) and rat-derived anti-BrdU
(1:10 000; #MCA2060, Serotec, Oslo, Norway). The secondary antibodies were applied in
two phases: the first was rabbit-derived biotinylated anti-rat IgG (1:200; #BA-4000, Vector
Laboratories). Antigen was visualized using glucose-oxidase-DAB solution, containing 1%
nickel ammonium sulphate, 1 mg/ml DAB (Pierce), 20% -D(+)-glucose, 0.4% ammonium
chloride, and 1 μl/ml glucose oxidase (#G-6891, Sigma). After extensive washing steps, in
the second phase, goat-derived biotinylated anti-mouse IgG (1:200; #BA-2000, Vector
laboratories) was applied and antigen was visualized using DAB.
Analysis of proliferating endothelial cells (I).
The total number of proliferating endothelial cells was determined using the optical
fractionator method (West MJ et al., 1991). Every third section from a 1-in-5 series was
sampled (ssf = 1/15). Proliferating endothelial cells were defined by the following criteria:
BrdU positive (BrdU+) cell nucleus with flattened or slightly cupped appearance found
within RECA-1 positive stained vessels (RECA-1+ / BrdU+). A virtual counting grid 213.9
μm (x-axis) by 213.9 μm (y-axis) was laid on the sections. Then, a three-dimensional
counting frame of 18.3 μm (x-axis) by 18.3 μm (y-axis) with height (z-axis) of 10 μm was
focused  through  a  known  depth  of  the  section.  Every  cell  that  came  into  focus  was
counted.  Total numbers of cells were estimated using the same formula as described for
hilar cells.
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4.10 STATISTICAL ANALYSIS (I, II, III)
Data were analyzed using SPSS for Windows (version 17.0). Data from spike counting
were analyzed using Repeated Measure Anova (RMA) with the Greenhouse-Geisser
correction factor. Differences between groups following semiquantitative scoring were
analyzed using the Chi-Square test. Differences between groups in other measurements
were analyzed using the Kruskall-Wallis test. If differences were found, post hoc analysis
was performed using the Mann-Whitney U test.  Correlations  were  analyzed  using  the
Spearman rank correlation test. Data are presented as mean ± standard error of the mean
(SEM).  A P-value less than 0.05 was considered significant.
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5. Results
5.1 STATUS EPILEPTICUS AND SEIZURE PHENOTYPE IN uPA-/- AND
uPAR -/- MICE (II, III)
In order to establish whether uPA and uPAR influence the severity of an epileptogenic
brain insult such as status epilepticus (SE) and the subsequent epilepsy outcome, the
severity of SE and the development of epilepsy was assessed in uPA and uPAR deficient
mice after intrahipocampal (i.h.) kainate-induced SE.
5.1.2 Severity of status epilepticus (SE) (II, III)
The severity of SE was investigated in mice lacking uPA (uPA-/-) or uPAR (uPAR-/-) and
wild type (Wt) controls. Preliminary analysis revealed that SE resolved 48 hr after kainate
injection; hence, the total number of spikes generated in EEG during the first 48 hr was
used to assess the severity of SE.
The total number of spikes was the same in uPA-/- mice and their Wt littermates (16
553 ± 1876 vs. 19 173 ± 3474) (p>0.05) (II, Fig. 7). Similarly, the evolution of SE and the total
number of spikes did not differ between uPAR-/- mice and Wt mice (40 626 ± 14 035 vs. 58
894 ± 11 426) (p>0.05) (III, Fig. 1).
5.1.2 Seizure phenotype characteristics (II, III)
uPA-/- and Wt mice showed no difference in latency to first spontaneous seizure (p>0.05),
seizure frequency (uPA-/-, 2.6 ± 0.49 sz/ day; Wt, 2.2 ± 0.4 sz/ day) (p>0.05) or seizure
duration (uPA-/-, 44 ± 1 s vs. Wt, 37 ± 5 s) (p>0.05) (II, Fig. 7).
uPAR-/- and Wt mice showed no difference in latency to first spontaneous seizure
(p>0.05), and seizure frequency (uPAR-/-, 1.1 ± 0.3 sz/ day; Wt, 1.5 ± 0.2 sz/ day) (p>0.05)
(III, Fig. 1). However, in contrast to uPA-/- mice, the seizure duration was longer in uPAR-
/- mice when compared to Wt mice (50.3 ± 1.8 s vs. 43.0 ± 2.6 s) (p<0.05) (III, Fig. 1).
Furthermore, increased seizure frequency was associated with the severity of SE (r=0.507,
p<0.05). However, this association was not seen in specific genotypes (uPAR-/- or Wt
mice).
5.1.3 Severity of behavioral seizures (III)
Behavioral analysis of seizures was performed only in uPAR-/- mice due to technical
issues related to our analogue video recording system. The analysis revealed that 74% of
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all seizures in uPAR-/- mice were scored at 3-5 (secondary generalized seizure) compared
to only 63% in Wt mice (p<0.01) (III, Fig. 1).
5.2 NEURODEGENERATION IN THE HIPPOCAMPUS (I, III)
5.2.1 Degeneration of principal cells
In the pilocarpine induced-SE rat model, the severity of neurodegeneration was assessed
at 2 d, 4 d, and 14 d post-SE.  At all time points, severe neurodegeneration was observed
bilaterally in pilocarpine injected animals with SE in the CA1 (p<0.05) and CA3 (p<0.05)
subfields of the hippocampus and hilus (p<0.05) of the dentate gyrus when compared to
saline injected controls (I, table 1).
In order to establish whether uPA-uPAR systems play a role in neurodegeneration
during epileptogenesis, the severity of neurodegeneration was assessed using uPA-/- and
uPAR-/-  mice.  The  results  of  neurodegeneration  and  GCL  dispersion  in  uPA-/-  mice  are
already published (for details see Lahtinen, 2010). Analysis was performed in uPAR-/- and
Wt mice at 4 d and 30 d following kainate-induced SE. Both genotypes experienced more
severe neurodegeneration in the ipsilateral more than contralateral hippocampus (III, Fig.
3). At 4 d, neurodegeneration was already more severe contralaterally in uPAR-/-
compared to Wt in the CA3 subfield (p<0.05) (III, Fig. 3). At 30 d neurodegeneration
progressed ipsilaterally in uPAR-/- and Wt mice in the CA1 subfield (p<0.05, compared to
4 d). Also, progression of neurodegeneration was observed in both genotypes in the
contralateral CA1 subfield (p<0.05, compared to 4 d) but with a more robust effect in
uPAR-/- mice than Wt mice (p<0.05) (III, Fig. 3).
5.2.2 Degeneration of hilar neurons
The severity of degeneration of hilar neurons following pilocarpine-induced SE in rats was
assessed semiquantitatively at 2 d, 4 d, and 14 d after SE. The results demonstrated a >50%
cell loss at all time points when compared to saline injected animals (I, table 1).
To investigate whether uPAR is involved in the degeneration of hilar neurons, the
total number of hilar cells was counted in uPAR deficient mice following kainate-induced
SE. The results showed that at 4 d after i.h. kainate injection uPAR-/- and Wt mice
experienced 63% and 90% ipsilateral hilar cell loss respectively when compared to saline
injected controls (p<0.01). The magnitude of hilar cell loss in kainate-injected animals was
similar in both genotypes (p>0.05). Contralaterally, kainate-injected uPAR-/- and Wt mice
showed a 39% and 43% cell loss respectively, compared to saline injected controls (p<0.01).
The magnitude of contralateral hilar cell loss in kainate-injected animals was similar in
both genotypes (p>0.05). At 30 d, kainate injected uPAR-/- and Wt mice revealed 89% and
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91% ipsilateral hilar cell loss respectively, compared to saline injected controls (p<0.001).
Contralaterally, uPAR-/- had 33% cell loss (p<0.05) while Wt mice showed no difference
when compared to saline controls (III, Fig. 3).
5.2.3 Degeneration and dispersion of granule cells
The effect on granule cell degeneration and dispersion of pilocarpine-induced SE, in rats,
was assessed semiquantitatively at 2 d, 4 d and 14 d post-SE. Less than 10% damage was
noticed at all time points. This was not statistically significant when compared to controls
(p>0.05) (I, table 1). However, no dispersion of granule cell layer was observed at all time
points analyzed after SE.
The role of uPAR in granule cell degeneration and dispersion was investigated in
uPAR-/- and Wt mice by measuring the volume of the granule cell layer at 30 d after i.h.
kainate-induced SE. The volume of the ipsilateral granule cell layer in uPAR-/- and Wt
mice was increased by 2-fold in both genotypes when compared to saline injected controls
(p<0.01). Contralateral granule cell layer volume did not vary between kainate and saline
injected uPAR-/- and Wt mice (p>0.05). Granule cell layer volume did not vary between
kainate injected uPAR-/- and Wt mice ipsilaterally or contralaterally (p>0.05) (III, Fig. 4).
About 5-10% damage in contralateral granule cells was noted in uPAR-/- (n=2) and Wt
(n=1) mice.
5.3 NEUROGENESIS IN THE DENTATE GYRUS (I, III)
The magnitude of neurogenesis after the induction of SE was assessed in the dentate gyrus
by  counting  the  number  of  DCX-positive  cells.  In  pilocarpine-induced  SE  rats,  the
magnitude of neurogenesis was assessed at 2 d, 4 d and 14 d Post-SE. No difference was
seen  in  the  total  number  of  DCX-positive  cells  at  2  d  and  4  d  when  compared  to  saline
injected controls. However, at these time points, DCX-positive cells in SE animals
appeared scattered along the subgranular zone with their dendrites seen within the
vicinity of soma as opposed to controls where there was a linear arrangement of cells
along the subgranular zone with dendrites extending into the inner molecular layer. At 14
d the number of DCX-positive cells was increased by 156% in SE animals compared to
controls (p<0.01) (I, Fig. 11).
The effect of uPA or uPAR deficiency on post-SE neurogenesis was analyzed in
uPA-/- and uPAR-/- mice at 20 and 30 d after i.h. kainate injection respectively. The results
from the uPA-/- mice are already published (for details see Lahtinen, 2010). Kainate-
injected uPAR-/- and Wt mice experienced a 142% (p<0.01) and 234% (p<0.01) increase in
DCX-positive cell number respectively, compared to saline treated controls. The total
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number of DCX-positive cells in the dentate gyrus did not vary between kainate injected
uPAR-/-  and Wt mice  (p>0.05)  nor  did it  vary in  any of  the  sub-regions  analyzed (hilus,
subgranular zone and granule cell layer). Many of the DCX-positive cells in uPAR-/- mice
were seen scattered and disorientated in the inner molecular layer of the dentate gyrus (III,
Fig. 5).
5.4 MOSSY FIBER SPROUTING IN THE DENTATE GYRUS (I, III)
The volume of mossy fiber in the dentate gyrus of rats after pilocarpine-induced status
epilepticus was assessed at 30 d and 60 d post-SE. There was already a significant increase
in mossy fiber sprouting at 30 d when compared with controls,  with a median score of 3
(p<0.05). At 60 d, the density of mossy fiber sprouting had increased even more when
compared with controls, with a median score of 5 (p<0.01).
The  effect  of  uPAR  deficiency  on  mossy  fiber  sprouting  in  the  dentate  gyrus  was
assessed in uPAR-/- and Wt mice at 30 d after i.h. kainate injection. Analysis revealed a 7-
fold increase in mossy fiber volume in kainate injected uPAR-/- and Wt mice when
compared to saline injected controls. However, the volume of mossy fiber was not
different between kainate-injected uPAR-/- and Wt mice (0.014 ± 0.004 mm3 vs. 0.014 ±
0.009 mm3, p>0.05) (III, Fig. 6).
5.5 BLOOD-BRAIN BARRIER IMPAIRMENT IN THE HIPPOCAMPUS (I,
III)
Blood-brain barrier (BBB) disruption in the hippocampus following pilocarpine-induced
SE in rats was assessed at 2 d, 14 d and 60 d after post-SE by measuring the degree of IgG
leakage into the brain. At 2 d, there was a 3.9-fold increase in IgG immunoreactivity in the
hippocampus when compared to controls (p<0.001). By 14 d post-SE, it dropped by 22%
from its 2 d values but was still about 3-fold above control values (p<0.01). IgG
immunoreactivity at 60 d was the same as at 14 d and 2.9-fold above control levels (p<0.01)
(I, Fig. 8).
To determine whether uPAR is involved in post-SE BBB impairment, the degree of
IgG leakage into the hippocampus was assessed in uPAR-/- and Wt mice at 4 d after i.h.
kainate injection. Kainate-injected uPAR-/- and Wt mice experienced a significant increase
in IgG immunoreactivity ipsilaterally and contralaterally when compared to saline treated
controls.  However,  no  genotype  difference  was  observed  in  the  magnitude  of  IgG
immunoreactivity ipsilaterally or contralaterally (p>0.05) (III, Fig. 7). It was observed that
the  degree  of  contralateral  IgG  immunoreactivity  was  associated  with  the  severity  of
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hippocampal damage (r=0.0675, p<0.05). This association was lacking in the ipsilateral
kainate-injected hippocampus.
5.6 INFLAMMATORY RESPONSE IN THE HIPPOCAMPUS (III)
In order to determine whether uPAR is involved in post-SE inflammatory response, the
magnitude of macrophage and T-cell response was assessed in uPAR-/- and Wt mice at 4 d
and 30 d post-SE. Saline injected animals demonstrated very mild microglia response and
no T-cell response at 4 d and 30 d after injection.
Macrophage immune response
At 4 d post-SE, ipsilateral macrophage response in kainate-injected uPAR-/- was mild
compared to in Wt (p<0.05). The difference was prominent in the CA1 and CA3 subfields
of the hippocampus (p<0.05) but not in the hilus of the dentate gyrus (p>0.05).
Contralateral macrophage response was similar in both genotypes. At 30 d, the magnitude
of ipsilateral macrophage response was similar in uPAR-/- and Wt mice. However,
contralaterally, macrophage response was more prominent in uPAR-/- mice compared to
Wt mice (p<0.05). This was seen particularly in CA1 and hilus (p<0.05) but not in CA3
(p>0.05) (III, Fig. 8, 9).
T-cell immune response
T-cell response at 4 d was mild in uPAR-/- mice compared to Wt mice, especially in the
CA3 subfield (p<0.05). At 30 d, the magnitude of T-cell response in uPAR-/- and Wt mice
increased exponentially  compared to  at  4  d.  However,  uPAR-/-  and Wt mice  showed no
difference in T-cell response at this time point (III, Fig. 10).
5.7 HIPPOCAMPAL VASCULAR MORPHOMETRY (I, II, III)
5.7.1 Endothelial cell proliferation, blood vessel length and diameter change (I, II, III)
In order to establish the occurrence of angiogenesis during epileptogenesis and whether
the blood vessels are affected by post-SE events, the number of proliferating endothelial
cells, blood vessel length and diameter were assessed in pilocarpine-induced SE rats.
Endothelial cell proliferation and total blood vessel length in the hippocampus was
assessed at 2 d, 4 d and 14 d post-SE. Endothelial cell proliferation was 3-fold at 2 d
(p<0.01), 10-fold at 4 d (p<0.001) and 3-fold at 14 d (p<0.05) when compared to controls.
Subfield analysis in the CA1, CA3 and molecular layer of the dentate gyrus revealed a
similar pattern, being elevated at 2 d, peaking at 4 d and returning to control levels by 14 d
(I, Fig. 6).
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The  total  blood  vessel  length  reduced  to  83%  of  control  values  at  2  d  post-SE
(p<0.05). It returned to control values at 4 d post-SE. However, by 14 d post-SE, it was 6%
above control levels (p>0.05). At 2 d, the most significant drop in blood vessel length was
observed in the CA1 subfield (88% of control values) (p<0.05). At 4 d, vessel length in all
subfields was similar to controls. At 14 d post-SE, the most pronounced increase in vessel
length was in the CA3 subfield (128% above control levels) (p<0.05) (I, Fig. 5).
The blood vessel diameter increased by 125% at 2 d and 111% at 14 d when
compared to controls. Increased vessel diameter was much more pronounced in the
hippocampal fissure where it was 125% at 2 d and 122% at 4 d when compared to controls
(I, Fig. 9).
5.7.2 Association of angiogenesis and hippocampal CBV and CBF (I)
To establish whether there are any functional changes associated with the observed blood
vessel length changes, the CBV and CBF were measured using MRI at 2 d and 14 d
following pilocarpine-induction in rats. The results revealed a 178% increase in CBV from
2 d to 14 d post-SE (p<0.05) in the same animal and a 124% increase when compared to
controls (p=0.88). This was associated with the increased vessel length observed from 2 d
to 14 d post-SE. No changes were observed in CBF from 2 d to 14 d post-SE in the same
animal (p=0.075), or when compared to controls (p=0.055) (I, Fig. 10).
5.7.3 Association of angiogenesis with neurodegeneration, neurogenesis and mossy
fiber sprouting (I)
In order to establish whether there is any interaction between the observed vessel length
changes and neuronal plastic changes during epileptogenesis, we assessed the correlation
between blood vessel length changes and neurodegeneration, neurogenesis, and mossy
fiber sprouting. No correlation was found between vessel length and neurodegeneration
in all hippocampal subfields analyzed (CA1 and CA3) at 2 d, 4 d and 14 d post-SE (p>0.05).
However, at 14 d, a strong association was seen between endothelial cell proliferation and
neuronal damage score (r=0.833, p<0.05) (I, Fig. 6). No correlation was seen between vessel
length or proliferating endothelial cells and neurogenesis at 2 d, 4 d and 14 d post-SE
(p>0.05). Neither was there any correlation between vessel length and mossy fiber
sprouting at 14 d and 60 d post-SE (p>0.05).
5.7.4 Effect of uPA or uPAR deficiency on vascular morphometry (II, III)
In an effort to establish whether uPA and uPAR play a role in vascular remodeling in the
hippocampus, during epileptogenesis, the blood vessel length was assessed in uPA or
uPAR deficient mice after i.h. kainate-induced SE.
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In uPA-/- mice, the blood vessel length was assessed at 20 d post-SE. Saline and
kainate-injected uPA-/- and Wt mice showed no difference in total blood vessel length,
ipsilaterally and contralaterally. Ipsilateral and contralateral blood vessel length was
similar in kainate-injected uPA-/- and Wt mice (II, Fig. 6).
On  the  other  hand,  in  uPAR-/-  mice  the  blood  vessel  length  was  assessed  at  30  d
after i.h. kainate-induced SE. Saline-injected uPAR-/- and Wt mice showed no difference in
total blood vessel length bilaterally. Total blood vessel length in kainate-injected uPAR-/-
and Wt mice was similar to saline-injected controls bilaterally. Kainate-injected uPAR-/-
and Wt mice showed similar ipsilateral blood vessel length. However, contralaterally, the
blood vessel length was shorter in uPAR-/- compared to Wt mice (p<0.05) (III, Fig. 11).
Septo-temporal profiling of vessel length changes in the hippocampus indicated a
significant  increase  in  blood  vessel  length  at  2  mm  caudal  to  injection  site  in  kainate-
injected Wt mice when compared to saline-injected controls. However, similar profiling in
kainate-injected uPAR-/- mice revealed no change when compared to their saline-injected
controls (III, Fig. 11).
Figure 3. Epileptogenic  network  alterations  in  uPA  and  uPAR  deficient  mice  after
intrahippocampal kainate-induced status epilepticus (SE). (A) In uPA deficient mice the
epilepsy phenotype did not vary with wild type mice. However, they demonstrated severe
neurodegeneration and impaired neurogenesis. (B) In uPAR deficient mice, the epilepsy
phenotype was severe compared to Wt mice. This associated with severe neurodegeneration,
impaired angiogenesis, impaired neuronal migration and delayed acute macrophage and T cell
response. Adapted from Crittenden et al., 2007
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Table 1. Summary of the epilepsy phenotype and epileptogenic network alterations in the
hippocampus of uPA and uPAR deficient mice following intrahippocampal injection of kainic
acid.
uPA uPAR
uPA-/- Wt uPAR-/- Wt
SE (total spikes/ 48h) 16553 ± 1876 19173 ± 3474  40626 ± 14035 58894 ± 11426
Epilepsy phenotype
sz latency (hr)
sz  frequency/ day
sz duration (sec)
total number of sz (30 d)
median sz score
52.2  ± 20.4 49.6 ± 11.4 88.0 ± 17.9 56.6 ± 11.7
2.06 ± 0.49 2.18 ± 0.44 1.1 ± 0.3 1.5 ± 0.2
44.0 ± 1.0 37.0 ± 5.0 50.3 ± 1.8 * 43.0 ± 2.6
61 ± 15 65 ± 13 33.0 ± 7.5 43.8 ± 6.3
NA NA 5 * 3
Neurodegeneration
Contra (% damage)
acute
chronic
Hilar cell number
ipsi
contra
GCL volume (mm3)
ipsi
contra
25%    (6 d) 33% (6 d) 33% * (4 d) 17% (4 d)
67% * (20 d) 33% (20 d) 50% * (30 d) 17% (30 d)
1308 ± 273 1071 ± 131 758 ± 232 680 ± 212
4555 ± 533 * 7515 ± 556 5033 ± 654 7068 ± 576
1.11 ± 0.11 1.27 ± 0.06 0.97 ± 0.09 1.06 ± 0.09
0.43 ± 0.03 0.37 ± 0.02 0.53 ± 0.02 0.53 ± 0.02
Neurogenesis (DCX)
(uPA, 20 d; uPAR, 30 d)
total
hilus
SGZ
GCL
6221 ± 878 * 10020 ± 459 16820 ± 2706 22920 ± 2893
556 ± 109 975 ± 175 417 ± 202 208 ± 86
5224 ± 775 * 8117 ± 488 13830 ± 2118 20030 ± 2483
442 ± 94 929 ± 225 2566 ± 583 2673 ± 476
BBB impairment (4 d)
ipsi
contra
NA NA 23.29 ± 2.28 24.03 ± 46.1
NA NA 7.19 ± 10.21 23.05 ± 5.17
Blood vessel length (m)
(uPA, 20 d; uPAR, 30 d)
ipsi
contra
2.39 ± 0.18 2.48 ± 0.09 1.96 ± 0.10 2.19 ± 0.06
2.53 ± 0.13 2.63 ± 0.09 1.89 ± 0.12 * 2.31 ± 0.09
Mossy fiber (mm3) (30 d) NA NA 0.014 ± 0.004 0.014 ± 0.009
Inflammation
Macrophage- 4 d
ipsi
contra
Macrophage - 30 d
ipsi
contra
T-cell (cells/mm3)
4 d
30 d
NA NA
25.59 ± 2.31 * 30.97 ± 0.92
NA NA 15.93 ± 3.66 19.33 ± 1.94
NA NA
19.12 ± 1.19 18.93 ± 0.64
NA NA 10.49 ± 1.35 * 5.98 ± 0.96
NA NA
NA NA 54 ± 14 * 134 ± 29
NA NA 185 ± 15 154 ± 15
Hippocampal damage is indicated as percentage of total cell loss. Hilar cell number, GCL
volume, neurogenesis  and blood vessel  length was assessed in uPA-/-  mice at  20 d post-SE
and in uPAR-/- at 30 d post-SE. BBB impairment and macrophage response are measured in
arbitrary units. Abbreviations: BBB, blood-brain barrier; contra, contralateral; DCX,
doublecortine; GCL, granule cell layer; hr, hour; ipsi, ipsilateral; m, meter; sec, second; SGZ,
subgranular zone; sz; seizure; NA, not analyzed. *p<0.05, as compared to Wt mice. Data are
presented as mean ± SEM
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6. Discussion
The  aim  of  this  thesis  was  first  to  investigate  the  interaction  between  the  cellular
reorganization processes known to occur during epileptogenesis, particularly exploring
the interaction between angiogenesis and neuronal plastic events, since common trophic
stimuli are involved in vascular network and nerve wiring (Carmeliet and Tessier-
Lavigne, 2005). The second part of the thesis focused on studying the mechanisms that
underlie the cellular reorganization processes occurring during epileptogenesis. The uPA-
uPAR system was chosen as a possible mechanism, since its expression is increased in the
hippocampus during epileptogenesis (Lahtinen et al., 2006, 2009; Iyer et al., 2010).
Furthermore, uPA and uPAR is implicated in several physiological and pathological
processes involving tissue remodeling (Sumi et al., 1992; Meiri et al., 1994; Irigoyen et al.,
1999; Wu YP et al., 2000). This suggests that uPA-uPAR may be a regulatory notch in
epileptogenic network reorganization.
The results presented in this thesis demonstrate the following: first, angiogenesis
restores hippocampal blood vessel length during epileptogenesis and correlates with
cerebral blood volume increase in hippocampus. Second, angiogenesis in the
hippocampus lacks association with regions of severe neurodegeneration as well as with
neurogenesis or axonal sprouting during epileptogenesis. Third, the epilepsy phenotype is
severe in uPAR deficiency but not uPA deficiency. Fourth, uPA or uPAR deficiency results
in severe neurodegeneration and impaired neurogenesis. Fifth, the process of angiogenesis
is impaired in uPAR deficiency, whereas it is not affected in uPA deficiency. Sixth, uPAR
deficiency results in a delayed acute inflammatory response which subsequently becomes
chronic. Lastly, uPAR deficiency does not affect post-SE BBB impairment or axonal
sprouting.
6.1 METHODOLOGICAL CONSIDERATIONS
Two SE animal models of human temporal lobe epilepsy (TLE) were used in the present
study, the pilocarpine-induced SE rat model and the intrahippocampal kainate-induced SE
mouse model. The reason why the pilocarpine-induced SE rat model was chosen is, firstly,
this model replicates some of the behavioral, electrographic and neuropathological
features of human TLE (Turski et al., 1984). Secondly, the model produces very severe
neurodegeneration, robust neurogenesis and mossy fiber sprouting, which suits the
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purpose of investigating the interaction between these processes and angiogenesis
(Cavalheiro et al., 2006).
The intrahippocampal kainate-induced SE mouse model shares some
electrographic, histopathologic and synaptic reorganization similarities with human TLE
(Bouilleret et al., 1999, Riban et al., 2002). This model was used because the C57BL/6 mouse
background is resistant to i.p. kainate or pilocarpine induced cell death (Schauwecker,
2002). To minimize variability in kainate response, appropriate control animals were
chosen. For uPA deficient mice, Wt littermates were used as controls. For uPAR deficient
mice, Wt mice of the C57Bl/6 genetic background produced from the same colony as the
knock-out were used as controls. Littermates were not used for uPAR-/- mice experiments
due to difficulties encountered during heterozygote breeding.
6.2 EPILEPSY PHENOTYPE IN uPA AND uPAR DEFICIENT MICE
There is increased expression of uPA and its receptor uPAR in humans and animal models
of temporal lobe epilepsy (Lahtinen et al., 2006, 2009; Iyer et al., 2010; Liu et al., 2010).
However, knowledge on the functional role of uPA and uPAR during epileptogenesis and
the subsequent epilepsy outcome remains poor. In order to address this question SE was
induced by intrahippocampal injection of kainate into mice lacking either uPA (uPA-/-) or
uPAR (uPAR-/-) and the development of epileptogenesis was followed by continuous
(24/7) video-EEG monitoring.
Our results indicate that in uPA-/- mice the severity of the initial insult (i.e. SE) did
not  differ  from  Wt  mice.  Analysis  of  the  epilepsy  phenotype  showed  no  difference
between uPA-/- and Wt mice. Similarly, the severity of SE did not differ between uPAR-/-
mice and their Wt controls. uPAR-/- and Wt mice showed no difference in latency to first
spontaneous seizure and seizure frequency. However, unlike uPA-/- mice, the seizure
duration was 16% longer in uPAR-/- mice when compared to Wt mice. Furthermore,
uPAR-/- mice demonstrated severe behavioral seizures, typically secondary generalized as
opposed to partial seizures in Wt mice. This indicates that the epilepsy phenotype is more
severe in uPAR-/- than in uPA-/- mice. However, it was interesting to note that the average
seizure frequency in uPA-/- and their Wt control mice was two times higher than that in
uPAR-/- and their Wt control mice, even though their (uPA-/- mice) total number of spikes
was only about half of that in uPAR-/- mice (see table 2). Whether this is related to the
experimental setting, since experiments were performed at different times, or genetic
background, remains to be investigated.
Previous studies have reported that uPAR-/- mice have a lowered threshold for
pentyleneterazol (PTZ)-induced seizures, showed epileptiform spiking in EEG, and about
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5.9% of them express spontaneous seizures during handling (Powell et al., 2003). However
the behavioral manifestations as reported by Powel and colleagues (2003), are different
from ours. They associated the seizure susceptibility and spontaneous seizures with a
reduced number of parvalbumin cells in the fronto-parietal cortex. Our preliminary data
did not reveal any major difference in the number of GAD67 or parvalbumin positive cells
between uPAR-/- and Wt mice. The differences between the laboratories can relate to
differences in the genetic background of uPAR-/- mice.
Taken together, our data suggest that lack of uPAR but not uPA can worsen the
epilepsy phenotype of acquired epilepsy. To understand the mechanisms associated with
the epilepsy phenotype in uPA-/- and uPAR-/- we next investigated the epileptogenic
circuitry reorganization at the site of primary focus, that is, the hippocampus.
6.3 NEURODEGENERATION IS AFFECTED BY uPA AND uPAR
Neuronal  loss  in  the  hippocampus and hilus  of  the  dentate  gyrus  are  amongst  the  most
prominent histopathological findings in the resected hippocampus of patients with
temporal lobe epilepsy (TLE) (Honavar and Meldrum, 1997). In the current study, we seek
to elucidate the evolution of neurodegeneration in the hippocampus and the dentate
gyrus, and whether the uPA-uPAR system is the underlying mechanism in this process.
Pilocarpine-induced SE resulted in severe cell loss in all hippocampal subfields and
in the hilus of the dentate gyrus as early as 2 days post-SE. However, very little damage
was seen in the granule cell layer. These findings are in line with previous studies in the
pilocarpine-induced SE model (Turski et al. 1983, de Lanerolle et al., 1989; Obenaus et al.,
1993; Houser and Esclapez, 1996). Analysis of neurodegeneration in uPA deficient mice
revealed that genotype had no effect on acute pyramidal cell loss in the hippocampus.
These data are in line with observations by Tsirka et al. (1997) who found no difference in
hippocampal neurodegeneration between uPA	
	 and Wt mice at 5 days after i.h. KA.
Thus, uPA does not have a significant effect on acute post-injury neurodegeneration.
However at chronic time points, neurodegeneration had progressed significantly in uPA-/.
On the other hand, acute pyramidal cell loss was severe in uPAR-/- and progressed
significantly by 30 days post-SE.
The robust  delayed cell  death in  uPA-/-  mice  suggests  that  uPA deficiency has  an
unfavorable effect on recovery by compromising the survival of remaining neurons. This
is supported by studies demonstrating poor recovery of uPA-/- mice after TBI (Morales et
al., 2006) or sciatic nerve crush (Siconolfi and Seeds, 2001). Also, previous in vivo and in
vitro  studies  in  glioma  models  have  suggested  that  blocking  uPAR  either  by  mRNA
interference or genetic deletion favors the expression of pro-apoptotic molecules like BAD,
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Bax and Bal over anti-apoptotic molecules, resulting in increased cell death (Besch et al.,
2007, Malla et al., 2012). Thus the increased cell death in uPA-/- and uPAR-/- mice could
partly be explained by the fact that uPA or uPAR deficiency reduces interaction of the
uPA-uPAR complex with various transmembrane receptors that initiate intracellular
signaling cascades for cell survival, proliferation, and growth (Blasi and Carmeliet, 2002;
Alfano et al., 2005; Hildenbrand et al., 2008). Another likely explanation for the facilitated
neurodegeneration  in  uPAR-/-  mice  is  an  augmented  activation  of  pro-apoptotic
mechanisms during SE, as discussed below, compared to Wt mice.
Taken together, our data demonstrate that only uPAR deficiency has an effect on
acute neurodegeneration whereas uPA or uPAR deficiency enhances delayed post-injury
neurodegeneration. This suggests that uPA and uPAR are involved in post-SE
neurodegeneration.
6.4 uPA AND uPAR ARE INVOLVED IN NEUROGENESIS
Status epilepticus induces remarkable neurogenesis in the dentate gyrus (Parent et al.,
1998; Scott et al., 1998; Kralic et al., 2005). Similarly, a significant increase in DCX positive
cells was noted at 14 d following pilocarpine-induced SE. We further investigated whether
the uPA-uPAR system is implicated in post-SE neurogenesis in the intrahippocampal
kainate-induced SE model.  In  this  model,  the  injected hippocampus contained only very
few  DCX  positive  cells,  suggesting  that  either  kainic  acid  itself  or  seizure-induced
exitotoxicity had killed the neuronal precursor cells. Therefore, analysis was limited to the
contralateral hippocampus. Considering the role of uPA and uPAR in cell proliferation
and migration, especially as depicted with cancer cells (Sumi Y. et al., 1992; Meiri N. et al.,
1994; Irigoyen et al., 1999; Wu YP et al., 2000), and in particular the role of uPAR-mediated
signaling in the activation of mitogenic activity of the hepatocyte growth factor (Moriyama
et al., 1999; Powell et al., 2001, Levitt, 2005),  we expected to see a change in the magnitude
of post-SE neurogenesis and migration of newly-born cells in the dentate gyrus in uPA-/-
or uPAR-/- mice.
The number of DCX positive cells in uPA-/- mice was unchanged when compared
to saline treated controls, whereas, in Wt mice, it increased by 18% when compared to
controls. In addition, subfield analysis showed less DCX-positive cells in the subgranular
zone and granule cell layer in uPA-/- compared to Wt mice. This indicates compromised
generation and migration of DCX-positive cells within the dentate granule cell layer of
uPA-/- mice. On the other hand, uPAR-/- and Wt mice showed a 1.4 and 2.3-fold increase
in DCX-positive cells respectively with no apparent genotype differences. However, many
of the DCX positive cells in uPAR were scattered and disorientated within the granule cell
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layer  and  inner  molecular  layer,  indicating  the  loss  of  directional  or  cued  proteolytic
migration.
Previous  studies  have demonstrated that  animals  with  severe  hippocampal  injury
have a more dramatic decrease in neurogenesis than animals with mild injury
(Hattiangady et al., 2004; Heinrich et al., 2006). However, this reason alone cannot justify
the mild neurogenesis in uPA-/- mice, since uPAR-/- also experienced severe
neurodegeneration but did not experience a poor magnitude of neurogenesis.
Mossy  fiber  sprouting,  one  of  the  most  studied  types  of  axonal  plasticity  in
experimental and human epilepsy (Sutula and Dudek, 2007), was noted in the dentate
gyrus in rats following pilocarpine-induced SE. A significant amount of mossy fiber
sprouting was observed at 30 d and 60 d post-SE. We next assessed whether uPAR
deficiency  affects  axonal  spouting.  As  expected  based  on  the  meagerness  of  newly-born
cells ipsilaterally in the septal hippocampus, there was no remarkable mossy fiber
sprouting ipsilaterally in uPAR-/- mice. Contralaterally, we found substantial sprouting
along the entire septotemporal axis without any difference between the genotypes. This
indicates that uPAR has no effect on axonal plasticity.
Taken together these data suggest that while uPA may modulate the course of
proliferation and maturation of neuronal precursors during neurogenesis, uPAR may
influence connectivity of the dentate gyrus by affecting the migration of newly-born cells.
6.5 ANGIOGENESIS IS AFFECTED BY uPAR BUT NOT BY uPA
There are several reports demonstrating increased vascular density in the resected
hippocampus of patients with temporal lobe epilepsy and in animal models (Sokrab et al.,
1989; Seiffert et al., 2004). In this study, we assessed the spatiotemporal evolution of
angiogenesis in the hippocampus after status epilepticus and studied whether the uPA-
uPAR system is involved in post-SE vascular remodeling.
At 2 d after pilocarpine-induced SE, the total blood vessel length as revealed by
RECA-1 staining reduced to 80% of control values but progressively recovered to control
values by 4 d and was even 6% above control level by 14 d. Similarly, endothelial cell
proliferation increased from 3-fold at 2 d to 10-fold at 4 d and reduced to 3-fold by 14 d.
Interestingly, endothelial cell proliferation correlated positively with blood vessel length at
4 d, suggesting that endothelial cells do actually contribute to vessel build-up. A similar
pattern of vessel length changes and endothelial cell proliferation was observed in the
molecular layer of the dentate gyrus and the CA1 and CA3 subfield of the hippocampus. It
was also revealed that at 2 d and 14 d post-SE, the blood vessel diameter increased in the
hippocampus and especially in the hippocampal fissure. This was probably as a result of
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clot formation since a number of clots were found at 2 d post-SE, and these clots were
present up until 14 d post-SE, though in lower numbers.
Rigau et al. (2007) reported a 200% increase in hippocampal vessel density at
chronic phase in Li-pilocarpine treated rats. Major discrepancies between this study and
ours are that blood vessels were detected using either endogenous peroxidase or von
Willebrand factor. Also, they did not use unbiased stereological analysis to quantify blood
vessel length. Similar to our findings is the study by Hellsten et al. (2005) which showed a
16% increase in hippocampal vessel length after 10 daily electroshocks when assessed at
21 d using unbiased stereology in RECA-1 stained sections.
In order to demonstrate whether the uPA-uPAR system is involved in post-SE
vascular remodeling, we analyzed the blood vessel length in uPA and uPAR deficient
mice after SE. Studies in the cancer field show that uPA-uPAR plays a role in endothelial
cell proliferation, adhesion, and migration during cancer angiogenesis (Deng et al., 1996,
Fibbi et al., 1998). Hence one will expect that post-SE vascular remodeling will be affected
in uPA or uPAR deficiency.
Stereological measurements of total blood vessel length revealed no difference
between  uPA-/-  and  Wt  mice  at  20  d  post-SE,  ipsilaterally  and  contralaterally.  Also,  the
total blood vessel length in kainate-injected uPA and Wt mice did not return to control
levels or beyond, which would have suggested ongoing angiogenesis. Whether or not this
is due to a short follow-up time warrants further studies. The finding that uPA deficiency
did not affect vessel length after kainate injection is in agreement with observations by
Lund et al. (2006) showing that wound healing in uPA-/- mice is moderately delayed but
not completely blocked.
On the other hand, there were no major changes in the total blood vessel length
ipsilaterally or contralaterally in uPAR-/- and Wt mice. However, when the vessel length
was estimated at different levels of the septotemporal axis of the hippocampus, Wt mice
with SE showed an increased vessel length over 2 mm caudal to the injection site. This was
not seen in uPAR-/- mice with SE, suggesting compromised post-SE vascular remodeling.
Taken together, these results demonstrate that uPAR seems to be mandatory for
angiogenesis since deficiency of uPA did not affect angiogenesis, which is in line with
observations in cancer studies (Deng et al., 1996, Fibbi et al., 1998, Bu et al., 2004, Lakka et
al., 2005).
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6.6 ASSOCIATION BETWEEN ANGIOGENESIS AND NEURONAL PLASTIC
EVENTS
Very few studies have demonstrated that vascular damage and consequent angiogenesis
induced by epileptogenic brain insults is prominent in the region of most severe
neurodegeneration, that is, in areas where most of the oxygen and glucose is needed for
the  repair  process.  Along  the  same  line  of  thought,  no  studies  have  demonstrated  an
association between angiogenesis and neurogenesis or axonal sprouting to support the
idea of common trophic stimuli at neurovascular niches during epileptogeneis (Carmeliet
and Tessier-Lavigne, 2005). In an attempt to resolve these questions, we investigated the
association between blood vessel length changes and neurodegeneration, neurogenesis
and mossy fiber sprouting after pilocarpine-induced status epilepticus.
Correlation analysis revealed no clear association between blood vessel length
changes and neuronal damage score. In addition, contrary to our hypothesis that
angiogenesis  would  be  most  robust  in  those  regions  with  severe  neurodegeneration,  the
number of proliferating endothelial cells did not correlate with the injury score in any of
the hippocampal subfields at early post-SE. These observations suggest that the milieu at
the site of neurodegeneration, including inflammatory response and cytokine release as
well as activation of extracellular proteinases, does not stimulate endothelial cell
proliferation but does not suppress it either in the model used (see Marchi et al., 2007;
Pitkänen and Lukasiuk, 2009).
In the present study, we expected the creation of an association between
angiogenesis and the degree of neurogenesis and axonal sprouting to support the idea that
common  trophic  stimuli  are  involved  in  nerve  and  blood  vessel  wiring  (Carmeliet  and
Tessier-Lavigne, 2005). Endothelial cell proliferation was observed as early as 2 d post-SE,
peaking at 4 d and dropping down to control levels by 14 d. On the other hand, like in
previous studies, a significant increase in DCX-positive cells was not observed earlier than
14 d (Hattiangady et al., 2004; Rao et al.,  2008).  This  suggests  that  the  time  course  of
endothelial cell proliferation after injury is much faster than neurogenesis, supporting the
finding that no association was observed between neurogenesis and angiogenesis during
early post-SE. However, this does not rule out the possibility that mechanisms driving
these processes could be overlapping. Such overlaps have been documented in works by
Palmer et al. (2000) where they showed neural progenitor cells in close contact with
endothelial cells in the infragranular layer of the dentate gyrus. In addition, studies have
demonstrated close association between newly-born immature neurons and remodeling
vasculature in the subventricular zone (SVZ), recruited by trophic action of stromal-
derived factor (SDF-1) and angiopoietin 1 (Ang1) upregulated by endothelial cells (Ohab et
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al., 2006). Similar cross-talk between these two processes has been demonstrated in
humans (Chairetti et al., 2008).
Previous studies have suggested that endothelial cell could secrete molecules
facilitating axonal growth (Carmeliet and Tessier-Lavigne, 2005; Ozdinler et al., 2006;
Chiaretti et al., 2008; Zacchigna et al., 2008). For example, Honma and colleagues (2002)
were able to show using artemin (ARTM) deficient mice that ARTM, a vascular-derived
neurotrophic factor, promotes migration and axonal projections of sympathetic
neuroblasts.  After  SE,  a  condition  known  to  trigger  a  remarkable  growth  of  granule  cell
axons or mossy fibers, we did not, however, find any association between the number of
proliferating endothelial cells or the vessel length and density of mossy fiber sprouting in
the dentate gyrus. Also, the time courses of endothelial cell proliferation and mossy fiber
sprouting were different. Sprouting continues for several weeks to months. These data
suggest that, after SE, the mechanisms maintaining angiogenesis and axonal sprouting
may be separate. Whether there is overlap in the molecular mechanisms that trigger both
phenomena at early post-SE phase remains to be explored.
6.7 INFLAMMATION IS MODULATED IN uPAR DEFICIENT MICE
A growing amount of evidence suggests that inflammation plays a role in epileptogenesis
and epilepsy (Ravizza et al., 2008; Maroso et al., 2010; Vezzani et al., 2009). Microglial
activation and leukocyte infiltration in sclerotic tissue of patients with mesial temporal
lobe epilepsy (TLE) and animal models of TLE contributes to the development of epilepsy
(Fabene et al., 2008). uPAR is expressed by activated microglia/macrophages after various
brain injuries, including SE, but its function in these cells is unknown (Beschorner et al.,
2000). In addition, previous studies have shown that uPAR is expressed in stimulated T
cells, and it is involved in their migration, differentiation, and phagocytosis via its
interactions with integrins on the cell surface (Gyetko et al., 1994; Simon et al., 2000; Gyetko
et al., 2001; Smith and Marshall, 2010).
Here, we show using a CD68 antibody, which stains both the phagocytotic
peripheral macrophages and resident microglia, that at 4 d post-SE, the acute hippocampal
macrophage response in uPAR-/- mice was milder than that in Wt mice. Interestingly, the
CD68 response in uPAR-/- mice was also milder in the extrahippocampal areas like the
amygdaloid complex and the hypothalamus. Even though the overall macrophage
response became alleviated over the 30-d follow-up, dropping to 20-30% of that at 4 d
post-SE, the density of immunopositive CD68 cells in uPAR-/- mice remained 2-fold
higher in many hippocampal subfields, including CA1 as compared to that in Wt mice.
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We  show  that,  at  4  d  post-SE,  there  was  an  invasion  of  T  cells  into  the
hippocampus, which is in line with previous studies using the intrahippocampal kainate
model (Chen et al., 2004). However, the acute T-cell counts in the CA3 subfield of the
hippocampus in kainate-injected uPAR-/- mice were only about 40% of that in Wt mice.
This is in line with previous studies in experimental lung infection, demonstrating more
than 50% alleviation of acute T cell response in uPAR-/- mice (Gyetko et al., 2001). As we
show here the difference in T cell number was not related to the difference in blood-brain-
barrier damage as IgG immunoreactivity at 4 d post-SE was comparable between the
genotypes. A more likely explanation for the difference is the compromised migratory
capacity of T cells from peripheral blood to brain parenchyma in uPAR-/- mice.
Interestingly, contrary to the CD68 cells which decreased during the follow-up, T cell
counts in uPAR-/- mice showed a 10-fold increase over time, and reached the same level or
even beyond that in Wt mice during the 30-d follow-up.
These data demonstrate that uPAR is involved in post-SE inflammatory response,
by affecting the recruitment of inflammatory cells. Furthermore, this data shows uPAR is
not involved in post-SE blood-brain barrier impairment.
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7. Conclusions
The aim of this thesis was to study the interaction between the cellular reorganization
process known to occur during epileptogenesis, their functional implications and the
molecular mechanism that underlie these processes. Special focus was placed on the
interactions between angiogenesis and neuronal plastic event. The uPA-uPAR system was
investigated as a possible candidate mechanism in epileptogenic network alterations. The
main findings of this thesis can be summarized as follows:
1. uPAR but not uPA is implicated in the  severity of the epilepsy phenotype following
a brain injury such as SE
2. Epileptogenic network alterations following SE, such as neuronal cell loss and
neurogenesis, are regulated by uPA and uPAR
3. Vascular network changes post-SE correlates with functional changes in cerebral
blood  volume  in  the  hippocampus  but  lacks  association  with  neuronal  plasticity
during epileptogenesis.
4. uPAR plays a stronger role than uPA in the progressive vascular buildup in the
hippocampus during epileptogenesis.
5. uPAR  is  implicated  in  the  severity  of  the  inflammatory  response  during
epileptogenesis
In summary, this work provides novel information on the interaction of epileptogenic
network alterations. Furthermore, it extends our knowledge on the mechanisms involved
in these network alterations that are a potential target for therapeutic interventions.
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Temporal lobe epilepsy is the 
most common form of acquired 
epilepsy. This thesis explored the 
interaction between the cellular 
reorganization processes occurring 
during epileptogenesis, their 
functional implications, and the role 
of the urokinase-type plasminogen 
activator (uPA) and its receptor 
(uPAR) in epileptogenic network 
alterations. It shows that components 
of epileptogenic network alterations 
may have different temporal 
profiles, and the Plau and Plaur 
genes encoding for uPA and uPAR 
respectively are modifier genes for 
acquired epileptogenesis.
